HYGEIA GROUP

hygeia

INTERIM FINANCIAL REPORT

for the reporting period

January 1st 2010 to June 30th 2010

Pursuant to

Article 5, L. 3556/2007

Maroussi, August 27, 2010

CONTENTS

A. Statements by the Board of Directors representatives (PURSUANT TO ARTICLE 5, PARA. 2, L.3556/2007)

HYGEIA SA BoD members mentioned below:

1. Konstantinos Stavrou, BoD Chairman
2. Areti Souvatzoglou, CEO and
3. Antonios Michopoulos, BoD member,

In our abovementioned capacity, appointed for that purpose by the HYGEIA S.A Board of Directors, we hereby certify and declare that to our knowledge:

(a) HYGEIA S.A (hereinafter referred to as the 'Company') financial statements attached herein for the period 1.1.2010 - 30.06.2010, drawn up in accordance with the International Financial Reporting Standards, depict the true assets and liabilities, the net worth and the Company's P & L for the reporting period as well as of the enterprises included in the consolidation and considered as a whole, according to paragraphs 3-5 of L.3556/2007 and

(b) the BoD semester report truly illustrates the information required, pursuant to article 5, para. 6, L.3556/2007 and the Capital Market Commission BoD decisions.

Maroussi, August 24, 2010

Certified by,

Konstantinos Stavrou	Areti Souvatzoglou	Antonios Michopoulos
BoD Chairman	Chief Executive Officer	Board of Directors member

B. Certified Auditors' Review Report

Addressed to **THE DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA S.A. shareholders**

Introduction

We reviewed the attached and consolidated concise financial position statement of **'DIAGNOSTIC & THERAPEUTIC CENTER OF ATHENS 'HYGEIA S.A'.'** (the company) and its subsidiaries dated June 30th 2010, the relevant concise corporate and consolidated total income statements, the statements of changes in equity and cash flows of the semester ended on that date and the selected explanatory notes making up the interim concise financial information, constituting an integral part of the semester financial report of article 5, L.3556/2007. The Company Management assumes the responsibility to compile and present this interim, concise financial information, based on the International Financial Reporting Standards, as adopted by the European Union and applied in the Interim Financial Report (International Accounting Standard «IAS 34»). Our task is to draw a conclusion on this interim concise financial information based on our review.

Review scope

We carried out our review according to the International Standard on Review Engagements (ISRE) 2410 «Review of Interim Financial Information Performed by the Independent Auditor of the Entity». The interim financial information review consists in implementing procedures for seeking information mainly by persons in charge of financial and accounting issues and in applying critical analysis and other review procedures. The scope of a review is substantially smaller than an audit performed according to the International Accounting Standards, not allowing us, therefore, the certainty of being cognizant of all the significant issues highlighted in an audit. Therefore, the present review does not constitute an audit opinion.

Conclusion

Based on the review carried out, from any substantial perspective, we have not observed anything leading us to the conclusion that the interim financial information attached has not been drawn up according to IAS 34.

Report on other legal and regulatory issues

Following the review, we ascertained that the semester financial report content, according to article 5, L. 3556/2007 is consistent with the interim, concise financial information attached**.**

Athens, August 27, 2010

The Certified auditor

Manolis Michalios
Institute of Certified Public Accountants of
Greece (SOEL) registration no.25131

Grant Thornton

Chartered Accountants Management Consultants
56, Zefirou str., 175 64 Palaio Faliro
SOEL Reg. No 127

C. Interim Report by the Board of Directors

Interim Report by the Board of Directors
OF THE COMPANY D.T.C.A. HYGEIA S.A.
ON THE CONSOLIDATED AND COMPANY FINANCIAL STATEMENTS
FOR THE PERIOD FROM 01/01/2010 TO 30/06/2010

Dear Shareholders,

Pursuant to the provisions of law 3556/2007, we submit herein the BoD semester report for the closing company period from 01/01/2010 up to 30/06/2010, drawn up and in agreement with the relevant provisions of law 3556/2007 and the pertinent Capital Market Committee executive decisions issued on this law.

This report outlines the financial developments and performances during the reporting period for the Group and the Company for the closing period, the significant events having taken place during this period and the impact thereof on the semester financial statements as well as on activities growth prospects for the current financial year second semester . Moreover, the main risks and uncertainties the Company is likely to face during the second semester 2010 are also described along with the important transactions concluded between the Company and its related parties.

(A) FINANCIAL DEVELOPMENTS AND PERFORMANCES OF THE REPORTING PERIOD

During the 1H2010 the Group Management, taking into consideration the prevailing conditions in South-East Europe markets, proceeded to a series of corporate acts and strategic options guided by high quality healthcare services provision and the Group's internal value enhancement.

The Ordinary General Meeting held on 7/6/2010 of HYGEIA S.A. resolved upon the Company's proceeding to the distribution of an mount of € 0.15 per share in the form of capital return (constructive dividend), with the possibility to reinvest whole or part of capital return.

On 11 January 2010 it was announced that the 100% subsidiary Y – LOGIMED SA, acquired the remaining 30% of BIO – CHECK INTERNATIONAL Private Multi-medical Facility Iatriki SA share capital, against a consideration of € 450,000, assuming thus 100% control of this company.

All the above combined with a sound management sustained the Group's growth despite the international economic crisis leading to deceleration of the economic activity in South-East European markets.

Financial figures are reflected on the consolidated and company data as follows:

REVENUES: At consolidated level, the Group Revenues stood at €171.78 m. posting a decrease of 6.13%. This decrease is attributed to the negative impact from the austerity measures announced by the Greek government ana have led to a shrinking of the available income, to limited financing and to increase of the operating cost with the levy of direct and indirect taxes. HYGEIA S.A revenues dropped by 1.85%, standing at €72.69 m. A similar revenues decline was also observed in MITERA whereas Y-PHARMA S.A. revenues posted an increase. In particular, MITERA S.A revenues decreased by 14.36% and stood at €40.40 m. and Y-PHARMA S.A. revenues increased by 6.32% at €16.19 m.
EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION (EBITDA): The consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) declined by 67.92% to € 9.94m. The consolidated EBITDA margin stood at 5.79%. HYGEIA S.A EBITDA stood at €11.11 m., posting a decline by 24.79% and the EBITDA margin as a percentage on sales stood at 15.29%. MITERA EBITDA stood at €1.81 m., whereas the EBITDA of LETO stood at €0.76 m.

EARNINGS BEFORE INTEREST AND TAXES (EBIT): The consolidated operating loss (EBIT) stood at €-0,42 m. The consolidated **(EBIT margin)** stood at -0.25%, mainly due to revenues decline of subsidiaries operating in a strongly competitive environment and due to total consolidation of foreign subsidiaries being at a restructuring phase. HYGEIA S.A operating profit stood at € 6.98 m., posting a decline by 36.87% and the **(EBIT margin)** as a percentage on sales stood at 9.60%.

PROFIT BEFORE TAX: The Group's consolidated losses before tax stood at €-4,67 m. mainly due to a gross profit decline from the overall negative financial circumstances. HYGEIA S.A profit declined by 67.53% at €4.82 m. MITERA profit before tax reached €0.2 m., LETO profit before tax reached €0.26m. .

NET PROFIT AFTER TAX & MINORITY RIGHTS: The Group's net losses stood at €-6.01 m. The existence of losses after tax at consolidated level is due to: (a) gross profit shrinking due to austerity measures, (b) windfall tax levied amounting to € 3.8 m. due to profitability, (c) foreign subsidiaries, which posted losses during the reporting period. At company level, profit after tax decreased by 86.02% at €1.85m., mainly due to lack of revenues from dividends during the current period. Finally, MITERA net losses approached € -1.57 m., while LETO losses reached €0.11m.

LOANS – CASH BALANCES: The Group's total bank borrowing (long term and short term) stood at € 195.2 m. against € 192.03 m. on 31.12.2009 and the Company's total borrowing stood at € 115.3 m. against € 108 m. on 31.12.2009. Respectively, the Group's and Company's cash balances during the same period stood at € 29.05 m. and € 17.8 m. respectively.

CAPITAL RETURN : Capital return (constructive dividend) by the parent company for the financial year 2009 από τη μητρική εταιρεία για την οικονομική χρήση 2009 of € 0.15 per share, of € 24.5 m total amount, was approved by the Ordinary General Shareholders Meeting held on June 7th 2010.

CASH FLOWS FROM OPERATING ACTIVITIES: The consolidated net operating cash flows amounted to €18.4 m. against € 20.3 m. last year. The company's net operating cash flows approached €4.9 m. against € 2.4 m. last year.

(B) SIGNIFICANT EVENTS DURING THE FINANCIAL YEAR FIRST SEMESTER

On 11 January 2010 it was announced that the 100% subsidiary Y – LOGIMED SA, acquired the remaining 30% of BIO – CHECK INTERNATIONAL Private Multi-medical Facility Iatriki SA share capital, against a consideration of € 450,000, assuming thus 100% control of this company.

On 28 January 2010, the Board of Directors elected as Executive Member Mr. Antonios Michopoulos to replace the resigning Executive Member, Mr. Floyd-Anthony Rapp.

The amount of lump-sum extraordinary contribution for social responsibility under article 5, L.3845/2010 on the total net income of the Group for fiscal year 2010 amounts to €3.8m, of which the amount of €1.7m concerns the parent company. The above amounts will encumber the results of 2Q 2010 on consolidated and company basis respectively.

(C) PROSPECTS-DEVELOPMENTS OF ACTIVITIES FOR THE B' SEMESTER OF THE CURRENT FINANCIAL YEAR

HYGEIA Group management, anticipating the general tendencies and challenges arising from the global financial crisis having afflicted South-East European economies, adjusted its business plan by adopting a selective growth strategy in South-East Europe and capital restructuring of HYGEIA S.A in order to safeguard the Group. In particular, during 2009 the Company proceeded to an early total repayment of € 300m. Convertible Bond Loan (C.B.L.) (January '09) and to a Share Capital Increase of € 83m total amount (November '09), resulting in a rapid improvement of leverage ratios and a dramatic cut of interest charges. The results from this decline of interest charges will be visible throughout the current financial year compared to the financial year 2009.

Today we are at the implementation process of austerity measures by the Greek Government and rigorous control by the International Monetary Fund (IMF) and the EU institutions as to their unfailing enforcement in order to drastically cut Public Debt, apply structural changes (pensions, opening up of closed professions, shrinking of the public sector, etc) and strengthening of the country's competitiveness. The results from the austerity measures enforcement, according to the Memorandum of Understanding (MoU) between the Greek Government, the European Central Bank (E.C.B), the I.M.F and the Eurozone countries estimate that the faithful implementation of austerity measures and structural changes will revive the Greek Economy growth after 2012. For the years 2010 and 2011 unemployment is set to increase (up to 15%) and the recession faced by the Greek economy in 2009 to deepen (to 4% in‘10, and 2.6% in ‘11).

Therefore, the growth of Greek economy, accounting for almost 85 % of HYGEIA Group revenues, will stall compared to developed economies growth.

In addition, during this difficult year for the Greek economy, HYGEIA Group will have to tackle the negative consequences of the austerity measures that have been announced, such as deterioration of consumer confidence, further reduction of households disposable income, unemployment increase, reduction of consumer spending, limited funding by Credit Institutions to consumers and enterprises, restructuring of private insurance market, inflation rise (on average 4.1% in 1 H 2010) and increase of operating cost due to higher indirect taxation (V.A.T, Excise Duty, etc), and due to higher taxation of distributed profit by 40% instead of 10% in effect during the fiscal year 2009. The forecasted decline in the tourism sector during the critical summer period and the increased limitations of liquidity are anticipated to render business conditions in Greece particularly demanding, expected to continue throughout the year.

It is obvious from the above that the prospects for the domestic healthcare services provision sector for 2H 2010 and the midterm period are linked to Greek economy progress. The current financial recession and the macroeconomic imbalances of Greek economy portray an environment of uncertainty and affect all sectors of economy, including the healthcare services provision sector and obviously the incontestable leader of the sector, HYGEIA Group.

HYGEIA Group management, keeping abreast with the general tendencies and challenges of the domestic and international sector of private healthcare services, in combination with the continuously increasing needs of patients for new and integrated services, has adopted an ongoing, dynamic Group operations growth, placing emphasis on enhancing Group operating performance and on providing new healthcare services. Similarly, the Group keeps on operating for its stakeholders long term interest, focusing on introducing value-added services, on investing in cutting edge technology, on providing innovative services in niche markets, always making sure that healthcare services are of top quality, respecting human beings, society and the environment.

In this context, HYGEIA’s Group management, forecasting further deterioration of the Greek economy, proceeded during the last 9-months with the introduction of new innovative valued-added services, the continuous training of personnel and the continuous improvement of the provided services, through cutting-edge technology investments and refurbishment of its building facilities. In particular, HYGEIA Group acquired 5 ultra-modern linear accelerators (3 in Greece and 2 in Albania), proceeded with the installation of Axesse Stereotactic Body Radiotherapy system, the installation of γ-Knife Perfexion, the only machine in Greece and the 4th in the world for Stereotactic Brain Radiosurgery, the provision of pay TV facility in patients rooms, the creation of a VIP floor at HYGEIA Hospital and the possibility of admission and discharge in the room, while the renovations on the hospitalization floors of MITERA and LETO maternity hospitals are under way.

Aiming at continuous improvement of services, HYGEIA, in January 2010, following an intensive two-year preparation, became the first and only hospital in Greece to have been accredited by the standard J.C.I (**Joint Commission International**), the top accreditation worldwide enjoyed only by 90 hospitals in Europe and 250 worldwide. J.C.I standard application upgrades the quality of hospitalization services provided as it ensures:

application of a patient-centered quality system focusing on every patient's needs, compliance with the International Patient Safety Objectives, fixed every year by the J.C.I and the W.H.O (World Health Organization), recording of patient-related information in the medical file, ensuring thus access to all healthcare professionals in order to provide prompt and specialized care, adoption of international clinical practice protocols and continuous integration of new ones to cover the entire range of services, elaboration of an ongoing training mindset, so that the personnel becomes the spearhead of knowledge and progress in the healthcare sector, elaboration of emergency plans to provide a safe environment for patients, individuals being diagnosed, escorts, visitors and employees, performance monitoring by means of quality indicators, being constantly expanded to integrate new ones for the entire range of services.

The Group's management, fully aware that the economic crisis afflicting Greece and the continuous decline of the disposable income due to the austerity measures shall create an adverse business environment, and being also aware of the Organization's social role and responsibility in the current challenging economic conjuncture, decided **the full V.A.T absorption** that was imposed for the first time in the domestic healthcare services providers so as not to encumber customers, while also deciding the introduction of economic packages for patients with limited financial capabilities. It is obvious that the V.A.T absorption shall have a negative impact on the Group's profit margins.

Furthermore, we move with a swift pace towards the full organizational restructuring and operational consolidation of the Turkish subsidiary Genesis Holding (SAFAK Group), while also taking swift steps towards the restructuring of Cypriot subsidiaries aiming to bolster the consolidated financial data and to enhance the Group's geographical diversification, mitigating risk exposure in Greece and, by extension, country risk.

Similarly, HYGEIA Group completed the construction of a private hospital in Albania, which is expected to further enhance the geographical diversification of the Group, further decreasing Group's exposure in Greece. The new ultramodern hospital in Tirana commenced operations on July 1st 2010 with initial capacity of circa 120 beds offering a General Hospital, Pediatric and Maternity Clinic, covering high level services for all cases, from diagnosis to their treatment. In full swing **HYGEIA HOSPITAL TIRANA** will offer 220 beds, 12 operating rooms, 5 labor rooms, 16 I.C.U beds. The new hospital constitutes the largest investment (approximately € 60 m.) in the healthcare services provision sector in Albania, equipped with cutting-edge technology and is expected to become a reference standard in the entire South-East Europe, offering high quality healthcare services not only in Albania but also in the neighboring countries, such as the Former Yugoslavian Republic of Macedonia, Kosovo and Montenegro. HYGEIA HOSPITAL TIRANA ultramodern facilities are located in a multi-storey building, covering a total surface of 25,129sq.m. in a land plot of 13,000 sq.m in the area of Kashar, Tirana, with easy access as it is surrounded by the Motorways SH2 and SH1/E762, connecting the capital of Albania with Duress and Northern Albania. The management does not expect HYGEIA HOSPITAL TIRANA to substantially reinforce the Group's financial figures during the financial year 2010, as it will operate only for 6 months and therefore, maturity of the investment within the current fiscal year is not feasible, while the pre-opening expenses of the first semester standing at € 1.1m, such as personnel recruitment and training, supply of pharmaceutical and consumable medical products etc have encumbered the Group's results during the reporting period.

Based on published articles during the 4th Quarter, a new maternity clinic is expected to open in the South Suburbs of Athens. HYGEIA Group and its maternity clinics, MITERA and LETO, in particular are taking the necessary measures to ensure the least possible impact on their figures.

In the framework of this strategy, **MITERA** upgraded the quality of the services provided enabling women opting for a second class position to be accommodated in a three-bed room instead of a four-bed room without extra financial charge. Moreover, MITERA offered valued-added services such as **MITERA at home**, developed a medical cosmetics department, a dermatology clinic and finally created the first in Greece integrated Breast Clinic in a private hospital, in exclusive cooperation with top breast surgeons from Cambridge University Hospital. The aforementioned new services, notwithstanding the diversification of services provided by the Hospital, are also expected to increase cross selling. MITERA Maternity Hospital carried out an expansion of the operating rooms adding 6 new operating theaters, while proceeding with the refurbishment of the hospitalization infrastructure and with the investment program upgrading of the cutting-edge technology equipment. In particular, O.D.S (One-

Day Surgery Centers) renovation has been completed, while the renovation of hospitalization floors (5^{th}, 6^{th} and 7^{th}) is soon to be completed; 64-section CT unit has been installed.

LETO Maternity Hospital, being a pioneer, as always, took steps towards offering innovative, value-added services joining niche markets, such as **vaginal delivery 'as at home'**, in designated areas not resembling to a hospital, the possibility of **Water labor**, and **'Rooming in',** with the possibility of co-habitation of the infant in the same room with its mother since the first moment of birth for 24 hours per day; the maternity hospital is running a renovation program for all hospitalization floors, with the third floor having been fully renovated.

In a nutshell, the strategic initiatives of the Group management have the following objectives: its vertical integration, further mitigation of country risk (through the geographical expansion in South-East Europe, the preservation of the Group's leading position amidst an adverse economic environment and the exploitation of any opportunities to be created and finally the effective treatment of the negative repercussions of the Greek public debt crisis.
In particular, to deal with the crisis, the management's priorities for the B' Semester 2010, focus on retention of the workforce, debt reduction, capital expenditures curtail, securing of assets, further decrease of assets from the broader public sector (e.g. Insurance Funds), on the optimal management of the working capital capitalizing at the same time on the synergies within the Group, so that it remains competitive in the long run.

We remain committed to the four axes of the Group's strategy: the geographic diversification, the continuous improvement of competitiveness, the vertical integration of activities, and the focus on human resources and Corporate Social Responsibility guided by the long-term interests of our stakeholders and the increase of the Group's shareholders value. Benefactor in the fulfillment of our targets remains the largest entrepreneurial group in Greece, MARFIN INVESTMENT GROUP SA, HYGEIA Group being a subsidiary thereof.

(D) MAIN RISKS AND UNCERTAINTIES FOR THE CURRENT FINANCIAL YEAR B' SEMESTER

HYGEIA Group operates in the field of primary and secondary care offering integrated healthcare services. The private healthcare services sector in Greece is characterized by particularities deriving from the dominant position traditionally held by the public sector in healthcare services provision. However, the public sector weakness to cover a continuously increasing demand and offer quality healthcare services led to an important growth of private clinics. With the growth rate of private sector healthcare services estimated to reach 9% in 2010, it becomes obvious that the sector in Greece represents a particular potential and perspective to which the companies participating in it are called to respond. HYGEIA Group results and progress are directly affected by Group activities against the continuous growth in the healthcare sector and by the capitalization of its potential for further growth. Any failure by HYGEIA Group to respond to the new conditions could have negative impact on its financial situation and its operating results.

1. Competition-related Risk

In the last years, the private sector healthcare services registers an ongoing growth with the 10 largest companies of the sector concentrating almost 60% of its total revenues, with HYGEIA Group, the largest group of the sector concentrating 14%, highlighting thus the vehement competition between the sector's largest companies. Unavoidably, this competition is geared towards enrichment of the provided services and swift response to the patient, expanding the existing facilities to house new departments. It should be stressed that several private clinics include from obstetrics clinics departments up to diagnostic centers in order to cover a broad range of services. One more field of competition observed in private healthcare services sector is the cooperation broadening between private units with insurance companies and the conclusion of contracts with social security funds to cover the medical charges for a broader number of patients. HYGEIA Group is today the incontestable leader in the Greek private healthcare services sector and through continuous improvement of such services it aims at not only maintaining this position but at becoming a sector forerunner offering new services. Nevertheless, in case the Company discontinues its development and investment policy not elaborating new forms of cooperation, its competitive position might be negatively affected.

2. Dependence on contracts with insurance companies

HYGEIA S.A. concludes long term agreements with the private insurance companies ETHNIKI, ING, ALLIANZ, ALICO etc. The signing of these agreements largely cuts the parent Company exposure to the corresponding risk.

3. Currency risk

Currency risk is the value fluctuation risk of financial instruments, assets and liabilities due to changes in exchange rates. The vast majority of Group transactions and balances are denominated in Euro; the same applies in loans except for Evangelismos Group holding a loan in Swiss franc to take advantage of lower interest rates. As a result, exposure to currency risks is evaluated as low. Since December 2008, with the acquisition of the private healthcare services group Genesis Holding A.S. (SAFAK Group), in Turkey, having the Turkish lira (TRY) as an operating currency, and the opening of HYGEIA HOSPITAL TIRANA in Albania, having the Albanian LEK as an operating currency, a probable currency risk might derive in the future from their consolidation. The Group management constantly monitors the currency risks that may arise and evaluates the need to take the relevant measures.

4. Interest Rate risk

The Group aims to attain the optimum balance/relationship between the borrowing cost and any impact on profit and cash flows possibly incurred by changes in interest rates. The Group monitors and manages borrowing and its overall economic strategy making a combined use of short term and long term borrowing. The Group policy is to continuously monitor interest rates tendencies and its financing needs. Moreover, another Group policy is to minimize exposure to cash flow interest rate risk as far as long-term financing is concerned. Long term financing is based on floating rate.

5. Liquidity risk

HYGEIA Group manages the liquidity needs by meticulously monitoring debts from long-term liabilities and daily payments. The liquidity needs are monitored at different time periods, on a daily and weekly basis and on a rotating period of 30 days. The long-term liquidity needs for the next 6 months and the upcoming year are determined on a monthly basis.

6. Credit risk

The Group continuously checks its receivables, either separately or jointly and integrates this information in the credit audit procedures. The Group receivables/sales come from Insurance Funds, Social Security Organizations, Insurance Companies and individual customers. The receivables from Insurance Funds and Insurance Companies present a minimum risk of losses. The probable credit risk is mainly related to individual customers with no insurance or with insured customers for the additional amount not covered by their insurance company.

The Group management considers that all abovementioned financial assets not impaired on previous compilation dates of financial statements are of high credit quality, including assets due.

None of the Group's financial assets has been mortgaged or insured under another form of credit insurance.

For trade and other receivables, the Group is not exposed to significant credit risks. The credit risk for liquidation receivables as well as for other short-term financial assets is considered negligible.

(E) TRANSACTIONS WITH RELATED PARTIES

This chapter includes the most important transactions and balances between the Company and related parties, as defined in the International Accounting Standard 24.

Significant Company transactions with related companies

During the financial year, the most important transactions carried out between the Company and its related parties were the following:

- The D.T.C.A HYGEIA S.A purchases regarding medical supplies and other supplies from the subsidiary company Y – Logimed amounting to circa € 11.2m.

MIG Group is a related party to the Company as there is a shareholding relationship and there are joint members in the companies' BoDs.

Maroussi, August 24, 2010
Authorized by the Board of Director

Konstantinos Stavrou
Board of Directors Chairman

D. Semester Financial Statements

The semester financial statements attached herein were approved by HYGEIA S.A BoD on 24.08.2010 and have been published by being uploaded on the internet, web address www.hygeia.gr and on ASE website where they will be available to investors for at least five (5) years since their compilation and publication date.

The concise financial data and information published on the Press, deriving from the financial statements, aim at providing readers with general information on the Company's financial situation and results but do not offer an integrated picture of its financial position, the Company and Group financial performance and cash flows, according to the International Financial Reporting Standards.

1. Concise Financial Position Statement on June 30th 2010

		THE GROUP Amounts in €		THE COMPANY Amounts in €	
	Note	30/06/2010	12/31/2009	30/06/2010	12/31/2009
ASSETS					
Non-Current Assets					
Tangible assets	8	266,767,867	253,497,556	105,653,103	104,147,161
Goodwill		230,146,335	230,146,335	0	0
Intangible assets		147,056,958	148,298,476	2,911,535	3,264,189
Investments in subsidiaries	9	0	0	361,246,205	361,246,205
Investment portfolio		761,793	761,793	11,739	11,739
Investment in properties		165,460	166,745	165,460	166,745
Other non current assets		465,943	488,220	185,334	228,370
Deferred tax asset		6,102,329	5,194,776	2,431,926	2,206,602
Total		**651,466,685**	**638,553,901**	**472,605,302**	**471,271,011**
Current Assets					
Inventories		11,096,140	10,758,815	2,193,476	1,898,736
Trade and other receivables		80,961,802	81,764,837	73,287,763	57,504,195
Other current assets		23,168,647	19,827,877	5,858,886	2,515,695
Cash and cash equivalents	10	29,050,730	29,111,297	17,806,957	21,695,860
Total		**144,277,319**	**141,462,826**	**99,147,082**	**83,614,486**
Total Assets		**795,744,004**	**780,016,727**	**571,752,384**	**554,885,497**
EQUITY AND LIABILITIES					
Equity					
Share capital		66,961,275	66,961,275	66,961,275	66,961,275
Share premium		310,727,050	310,931,854	310,727,051	310,931,855
Fair value reserves		13,059	39,042	0	0
Other reserves		6,147,001	4,731,608	4,992,681	4,212,607
Retained earnings		8,669,811	16,502,328	16,717,796	15,508,211
Equity attributable to parent's shareholders		**392,518,196**	**399,166,107**	**399,398,803**	**397,613,948**
Non-controlling interests		27,910,828	32,200,605	0	0
Total Equity		**420,429,024**	**431,366,712**	**399,398,803**	**397,613,948**
Non-current liabilities					
Deferred tax liability		50,250,403	50,173,061	8,102,416	7,908,205
Accrued pension and retirement obligations		13,164,943	12,927,007	7,856,929	7,858,687
Government grants		631,195	671,419	0	0
Long-term borrowings	11	34,893,400	35,990,429	0	0
Non-Current Provisions		12,304,608	11,945,909	2,889,246	2,739,246
Other long-term liabilities		615,820	290,391	74,529	74,597
Total		**111,860,369**	**111,998,216**	**18,923,120**	**18,580,735**
Current Liabilities					
Trade and other payables		62,710,541	48,371,751	25,528,196	22,083,050
Tax payable		13,082,207	7,674,978	4,523,553	428,573
Short-term debt	11	160,306,529	156,042,191	115,300,000	108,000,000
Current portion of non-current provisions		177,326	2,247,860	0	0
Other current liabilities		27,178,008	22,315,019	8,078,712	8,179,191
Total		**263,454,611**	**236,651,799**	**153,430,461**	**138,690,814**
Total liabilities		**375,314,980**	**348,650,015**	**172,353,581**	**157,271,549**
Total Equity and Liabilities		**795,744,004**	**780,016,727**	**571,752,384**	**554,885,497**

2. *Concise Total Income Statement for the period ended on June 30th 2010*

Income Statement			**THE GROUP Amounts in €**		**THE GROUP Amounts in €**	
	Note	**Note**	**30/06/2010**	**30/06/2009**	**01/04/2010 - 30/06/2010**	**01/04/2009 - 30/06/2009**
Continuing operations						
Sales	6	36	171,779,824	183,007,412	83,078,297	93,683,535
Cost of sales		37	(157,959,401)	(150,278,385)	(79,113,967)	(79,196,859)
Gross profit			**13,820,423**	**32,729,027**	**3,964,330**	**14,486,676**
Administrative expenses		37	(13,835,538)	(12,833,715)	(7,188,996)	(5,889,523)
Distribution expenses		37	(3,558,703)	(1,901,596)	(2,053,857)	(843,569)
Other income		38	4,160,015	5,821,726	2,053,875	1,869,342
Other expenses		39	(1,013,451)	(2,433,475)	(196,050)	(1,271,349)
Operating profit / (loss)			**(427,254)**	**21,381,967**	**(3,420,698)**	**8,351,577**
Other financial results		40	304,308	(114,330)	226,289	(124,438)
Finance costs		41	(4,813,282)	(8,663,101)	(2,629,909)	(3,486,178)
Financial income		42	264,671	3,007,082	62,905	557,957
Income from dividends			0	0	0	0
Share in net profit (loss) of companies accounted for by the equity method		43	0	(20,568)	0	0
Income (expense) from Joint Ventures		44	0	0	0	0
Profit / (Loss) before income tax	6		**(4,671,557)**	**15,591,050**	**(5,761,413)**	**5,298,918**
Income tax	13	45	(5,206,892)	(5,058,227)	(4,985,471)	(2,817,509)
Profit / (Loss) for the period from continuing operations			**(9,878,449)**	**10,532,823**	**(10,746,884)**	**2,481,409**
Discontinued operations						
Net profit from discontinued operations		46	0	0	0	0
Profit / (Loss) for the period			**(9,878,449)**	**10,532,823**	**(10,746,884)**	**2,481,409**
Attributable to:						
Owners of the parent	19		(6,013,996)	10,986,730	(8,048,008)	3,027,746
Non-controlling interests			(3,864,453)	(453,907)	(2,698,876)	(546,337)
Earnings before taxes, financing and investment activities and depreciations			9,940,218	30,982,980	1,841,366	13,171,980
Earnings before taxes, financing and investment activities and depreciations (Circular No 34, Capital Market Commission)			9,855,932	30,893,353	1,757,080	13,112,279
Earnings / (Loss) per share						
Basic earnings per share from continuing operations	19		(0.0368)	0.0875	(0.0493)	0.0241

Statement of Comprehensive Income	**Amounts in €**		**Amounts in €**	
	30/06/2010	**30/06/2009**	**01/04/2010 - 30/06/2010**	**01/04/2009 - 30/06/2009**
Net profit / (Loss) for the period	**(9,878,449)**	**10,532,823**	**(10,746,884)**	**2,481,409**
Other comprehensive income:				
Exchange differences on translating foreign operations	(437,241)	(1,100,611)	131,410	221,817
Exchange gain /(loss) on disposal of foreign operations recognized to profit or loss	0	0	0	0
Share of other comprehensive income of equity accounted investments :				
- current period	0	0	0	0
- reclassification to profit or loss	0	0	0	0
Other comprehensive income for the period before tax	**(437,241)**	**(1,100,611)**	**0**	**0**
Income tax relating to components of other comprehensive income	0	0	0	0
Other comprehensive income for the period, net of tax	**(437,241)**	**(1,100,611)**	**0**	**0**
Total comprehensive income for the period after tax	**(10,315,690)**	**9,432,212**	**(10,746,884)**	**2,481,409**
Attributable to:				
Owners of the parent	(6,090,687)	10,098,649	(6,769,156)	3,165,183
Non-controlling interests	(4,225,003)	(666,437)	(3,846,318)	(461,957)

The Group's consolidated financial statements on 30.06.2010 also include the results of "BIO-CHECK INTERNATIONAL Private Multi-medical Facility Iatriki S.A' consolidated with the full consolidation method, in contrast to the respective comparative period of 2009, when it was included for one month.

Income Statement		**THE COMPANY**		**THE COMPANY**	
		Amounts in €		**Amounts in €**	
	Note	**30/06/2010**	**30/06/2009**	**01/04/2010 - 30/06/2010**	**01/04/2009 - 30/06/2009**
Continuing operations					
Sales	6	72,691,046	74,061,735	35,529,609	37,356,802
Cost of sales		(61,509,795)	(60,396,129)	(30,262,585)	(30,717,416)
Gross profit		**11,181,251**	**13,665,606**	**5,267,024**	**6,639,386**
Administrative expenses		(3,912,944)	(3,506,064)	(1,991,486)	(1,859,331)
Distribution expenses		(707,621)	(657,148)	(543,282)	(456,072)
Other income		550,559	1,852,639	198,482	273,301
Other expenses		(131,423)	(297,149)	(59,442)	(249,555)
Operating profit / (loss)		**6,979,822**	**11,057,884**	**2,871,296**	**4,347,729**
Other financial results		0	(269,781)	0	(269,781)
Finance costs		(2,286,664)	(5,885,688)	(1,340,341)	(2,060,289)
Financial income		107,244	1,677,841	32,960	582,921
Income from dividends		17,500	8,256,583	17,500	8,256,583
Share in net profit (loss) of companies accounted for by the equity method		0	0	0	0
Income (expense) from Joint Ventures		0	0	0	0
Profit / (Loss) before income tax	6	**4,817,902**	**14,836,839**	**1,581,415**	**10,857,163**
Income tax	13	(2,970,027)	(1,615,989)	(2,208,385)	(1,434,345)
Profit / (Loss) for the period from continuing operations		**1,847,875**	**13,220,850**	**(626,970)**	**9,422,818**
Discontinued operations					
Net profit from discontinued operations		0	0	0	0
Profit / (Loss) for the period		**1,847,875**	**13,220,850**	**(626,970)**	**9,422,818**
Attributable to:					
Owners of the parent	19	1,847,875	13,220,850	(626,970)	9,422,818
Non-controlling interests		0	0	0	0
Earnings before taxes, financing and investment activities and depreciations		11,116,353	14,781,174	5,008,392	6,281,478
Earnings before taxes, financing and investment activities and depreciations (Circular No 34, Capital Market Commission)		11,096,362	14,761,513	4,988,401	6,271,163
Earnings / (Loss) per share					
Basic earnings per share from continuing operations	19	0.0113	0.1052	(0.0038)	0.0750

Statement of Comprehensive Income	**Amounts in €**		**Amounts in €**	
Net profit / (Loss) for the period	**1,847,875**	**13,220,850**	**(626,970)**	**9,422,818**
Other comprehensive income:				
Exchange differences on translating foreign operations	0	0	0	0
Other comprehensive income for the period before tax	**0**	**0**	**0**	**0**
	0	0	0	0
Other comprehensive income for the period, net of tax	**0**	**0**	**0**	**0**
Total comprehensive income for the period after tax	**1,847,875**	**13,220,850**	**(626,970)**	**9,422,818**
Attributable to:				
Owners of the parent	1,847,875	13,220,850	(626,970)	9,422,818
Non-controlling interests	0	0	0	0

3. Concise Statement of Changes in Equity of the period ended on June 30th 2010

THE GROUP

Amounts in €

	Share capital	Share premium	Revaluation reserves	Other reserves	Retained earnings	Total equity attributable to owners of the parent
Balance as of 1/1/2009	**51,508,673**	**258,756,457**	**0**	**7,785,354**	**22,065,756**	**340,116,240**
Dividends	0	0	0	0	(6,281,546)	(6,281,546)
Direct changes in Equity	0	0	0	0	165,396	165,396
Share capital decrease by share capital return to shareholders	0	(15,075,709)	0	0	0	(15,075,709)
Transfers between reserves and retained earnings	0	0	0	1,196,995	(1,196,995)	0
Share capital decrease	0	0	0	0	0	0
Impact from subsidiary purchase price finalization	0	0	0	0	0	0
Increase/(Decrease) of non-controlling interest from acquisition	0	0	0	0	0	0
Increase / (Decrease) of shares in investments in subsidiaries	0	0	0	(8,406,146)	0	(8,406,146)
Dividends to minority shareholders of subsidiaries	0	0	0	(39,000)	0	(39,000)
Stock option plans	0	0	0	286,147	0	286,147
Increase in Minorities due to purchase of interest in subsidiaries	0	0	0	0	0	0
Convertible Bond Revaluation Surplus	0	0	0	(2,481,499)	1,319,958	(1,161,541)
Transactions with owners	**0**	**(15,075,709)**	**0**	**(9,443,503)**	**(5,993,187)**	**(30,512,399)**
Profit for the period	**0**	**0**	**0**	**0**	**10,986,730**	**10,986,730**
Other comprehensive income:						
Exchange differences on translation of foreign operations	0	0	0	(888,080)	0	(888,080)
Other comprehensive income after tax	**0**	**0**	**0**	**(888,080)**	**0**	**(888,080)**
Total comprehensive income for the period after tax	**0**	**0**	**0**	**(888,080)**	**10,986,730**	**10,098,650**
Balance as of 30/6/2009	**51,508,673**	**243,680,748**	**0**	**(2,546,229)**	**27,059,299**	**319,702,491**
Balance as of 1/1/2010	**66,961,275**	**310,931,854**	**39,042**	**4,731,608**	**16,502,328**	**399,166,107**
Transfers between reserves and retained earnings	0	0	0	1,350,296	(1,350,296)	0
Additional equity offering costs	0	(204,804)	0	0	0	(204,804)
Dividends to minority shareholders of subsidiaries	0	0	0	0	0	0
Stock option plans	0	0	0	141,784	0	141,784
Increase in Minorities due to purchase of interest in subsidiaries	0	0	0	0	(494,208)	(494,208)
Transactions with owners	**0**	**(204,804)**	**0**	**1,492,080**	**(1,844,504)**	**(557,228)**
Profit for the period	**0**	**0**	**0**	**0**	**(6,013,996)**	**(6,013,996)**
Other comprehensive income:						
Exchange differences on translation of foreign operations	0	0	0	(76,687)	0	(76,687)
Income tax relating to components of other comprehensive income	0	0	(25,983)	0	25,983	0
Other comprehensive income after tax	**0**	**0**	**(25,983)**	**(76,687)**	**25,983**	**(76,687)**
Total comprehensive income for the period after tax	**0**	**0**	**(25,983)**	**(76,687)**	**(5,988,013)**	**(6,090,683)**
Balance as of 30/6/2010	**66,961,275**	**310,727,050**	**13,059**	**6,147,001**	**8,669,811**	**392,518,196**

THE COMPANY

Amounts in €

	Share capital	Share premium	Other reserves	Retained earnings	Total equity
Balance as of 1/1/2009	**51,508,673**	**258,756,457**	**6,735,151**	**7,316,202**	**324,316,483**
Dividends	0	0	0	(6,281,546)	(6,281,546)
Share capital decrease with capital return to shareholders	0	(15,075,709)	0	0	(15,075,709)
Transfer between reserves and retained earnings	0	0	404,042	(404,042)	0
Share-based payments	0	0	286,147	0	286,147
Convertible Bond Revaluation Surplus	0	0	(2,481,499)	1,319,958	(1,161,541)
Transactions with owners	**0**	**(15,075,709)**	**(1,791,310)**	**(5,365,630)**	**(22,232,649)**
Results for the period	**0**	**0**	**0**	**13,220,850**	**13,220,850**
Balance as of 30/06/2009	**51,508,673**	**243,680,747**	**4,943,841**	**15,171,423**	**315,304,684**
Balance as of 1/1/2010	**66,961,275**	**310,931,855**	**4,212,607**	**15,508,211**	**397,613,948**
Transfer between reserves and retained earnings	0	0	638,290	(638,290)	0
Expenses from share capital increase	0	(204,804)	0	0	(204,804)
Share-based payments	0	0	141,784	0	141,784
Transactions with owners	**66,961,275**	**310,727,051**	**4,992,681**	**14,869,921**	**397,550,928**
Results for the period	**0**	**0**	**0**	**1,847,875**	**1,847,875**
Balance as of 30/06/2010	**66,961,275**	**310,727,051**	**4,992,681**	**16,717,796**	**399,398,803**

4. Concise Cash Flows Statement of the period ended on June 30th 2010

Statement of Cash Flows

		THE GROUP Amounts in €		THE COMPANY Amounts in €	
	Note	**30/06/2010**	**30/06/2009**	**30/06/2010**	**30/06/2009**
Cash flows operating activities	20	**26,791,727**	**33,622,383**	**8,397,532**	**11,028,274**
Interest paid		(4,454,238)	(9,808,412)	(2,094,132)	(8,364,509)
Income tax paid		(3,661,133)	(3,523,157)	(1,170,685)	(239,560)
Net Cash flows operating activities		**18,676,356**	**20,290,814**	**5,132,715**	**2,424,205**
Cash flows from investing activities					
Purchase of property, plant and equipment	8	(21,148,019)	(21,594,056)	(5,233,673)	(5,107,978)
Purchase of intagible assets		(340,272)	(394,489)	(76,244)	(216,394)
Purchase of investment property		0	0	0	0
Proceeds from disposal of property, plant and equipment		229,059	92,601	0	61,000
Proceeds from disposal of investment property		0	0	0	0
Proceeds from disposal of available-for-sale financial assets		0	0	0	0
Increase in capital and additional paid-in capital of subsidiaries		0	0	0	0
Dividends received		0	0	15,750	9,631,235
Purchase of financial assets at fair value through profit and loss		0	0	0	0
Purchase of financial assets of trading portfolio		0	(31,959)	0	0
Sale of financial assets at fair value through profit and loss		0	0	0	0
Derivatives settlement		0	0	0	0
Acquisition /Sale of subsidiaries (less cash)		840	(22,823,993)	0	(20,964,038)
Acquisition of associates		0	0	0	0
Purchase of available-for-sale financial assets		0	(51,418)	0	0
Sale of financial assets held-for-sale		0	0	0	0
Interest received		83,833	1,761,342	37,549	1,677,841
Grants received		100,275	164,242	0	98,304
Loans to related parties		0	0	(10,795,522)	(1,033,742)
Loans to third parties		0	0	0	0
Receivables from loans to related parties		0	0	0	0
Investments in associates		0	0	0	0
Investments in subsidiaries		(450,000)	(1,050,021)	0	0
Investment cash flows from discontinued operations		0	0	0	0
Net Cash flow from investing activities		**(21,524,284)**	**(43,927,751)**	**(16,052,140)**	**(15,853,772)**
Cash flow from financing activities					
Proceeds from issuance of ordinary shares		0	0	0	0
Proceeds from issuance of ordinary shares of subsidiary		0	0	0	0
Additional equity offering costs		(269,478)	0	(269,478)	0
Proceeds from borrowings		20,946,655	247,488,635	15,200,000	220,000,000
Payments for borrowings		(17,227,054)	(348,399,787)	(7,900,000)	(341,015,300)
Payments for share capital dicrease to parent's shareholders		0	0	0	0
Payments for share capital dicrease to minority shareholders of subsidiaries		0	0	0	0
Dividends payed to parent's shareholders		0	0	0	0
Dividends paid to minority interests		(109,735)	(170,001)	0	0
Payment of finance lease liabilities		(552,291)	(431,308)	0	0
Interest paid		0	0	0	0
Sale/(Acquisition) of treasury shares		0	0	0	0
Capital return to shareholders		0	0	0	0
Loans from related parties		0	0	0	0
Sale/(Acquisition) of own bonds		0	0	0	0
Financing activities cash flows from discontinued operations		0	0	0	0
Net Cash flow financing activities		**2,788,097**	**(101,512,461)**	**7,030,522**	**(121,015,300)**
Net (decrease) / increase in cash and cash equivalents		**(59,831)**	**(125,149,398)**	**(3,888,903)**	**(134,444,867)**
Cash and cash equivalents at beginning of the period		29,111,297	199,576,107	21,695,860	189,807,965
Exchange differences in cash and cash equivalents		(736)	(461,835)	0	(269,781)
Net cash at the end of the period		**29,050,730**	**73,964,874**	**17,806,957**	**55,093,317**

5. Notes on the Interim Financial Statements of the period ended June 30th 2010

(amounts in euro unless stated otherwise)

1. General information

HYGEIA S.A. was established in 1970 by physicians who in their majority were professors at Athens University; since then, it operates in the field of primary and secondary healthcare services provision.

The Issuing Company is housed in a privately-owned building located at 4 Erythrou Stavrou Street & Kifisias Avenue in Maroussi, which has undergone several refurbishments. The administrative services of "HYGEIA Group" are housed in Maroussi Attica, at 30 Kapodistriou Ave. & Pentelikou Str. (GR- 151 23). The Company's internet address is www.hygeia.gr and its shares are listed on the Athens Stock Exchange.

In January 2006, MARFIN INVESTMENT GROUP acquired control of the Issuing Company and in the following months it took a number of investment initiatives (buyouts, mergers and new companies' incorporation) in line with the strategic goal of setting up the largest group focusing on the provision of integrated healthcare services in SE Europe. Today, the HYGEIA Group is present in 4 SE European countries and holds 10 private hospitals in Greece, Turkey Albania and Cyprus, of a total capacity of 1,848 licensed beds and a total of 84 operating theaters, 47 delivery rooms and 23 Intensive Care Units with 160 beds, employing approximately 4,500 employees and more than 4,000 associate physicians.

The Issuing Company numbers the following portfolio of hospitals: "D.T.C.A. HYGEIA", "GENERAL MATERNITY, GYNECOLOGIC & PEDIATRIC CLINIC MITERA", "LETO MATERNITY CLINIC", ""ACHILLION LIMASSOL", "EVAGGELISMOS PAFOS", "AVRUPA SAFAK HOSPITAL", "JFK HOSPITAL", "GOZTEPE SAFAK HOSPITAL", "ISTANBUL SAFAK HOSPITAL" and 'HYGEIA HOSPITAL TIRANA'.

HYGEIA Group is present in the primary healthcare sector through the AlfaLab Center of Molecular Biology & Cytogenetics, of the Diagnostic Center BIO-CHECK at the center of Athens and of the 'Multi-medical Facility of Western Attica; in Peristeri.

"HYGEIA" Group is also expanding in the stem cell banking sector by creating a network in Europe, the Mediterranean and the Middle East. "Stem-Health Hellas S.A." started operating in July 2008 in Greece. Finally, the "HYGEIA" Group owns companies focusing on the trade of special materials and consumables ("Y-LOGIMED S.A."), pharmaceuticals and all-purpose medical items ("Y-PHARMA S.A."), which supply the group's companies with the necessary medical and pharmaceutical products.

HYGEIA S.A." offers its services to private individuals as well as to patients seeking diagnostic services through public sector funds and social security organizations. Throughout its history the Group has aimed to combine high quality healthcare services with respect towards people, society and environment.

HYGEIA Group is a subsidiary company of «**MARFIN INVESTMENT GROUP S.A**» (MIG).

On 30.06.2010 HYGEIA S.A. total headcount was 1,221 employees against 1,156 on 30.06.2009, whereas the Group headcount was 4,521 employees against 4,226 on 30.06.2009.

2. Drafting base of interim Financial Statements

The interim financial statements have been prepared according to International Accounting Standard ("IAS") 34 "Interim financial reporting" and should be examined in conjunction with the published annual financial statements as at 31st December 2009, available on the Company's website.
The accounting principles and calculation methods used for the preparation and presentation of the interim financial statements are in compliance with those used for the preparation of the Company and Group's financial statements for the period that ended on 31st December 2009, except for the changes below.

3. Changes in Accounting Principles

The Company has adopted all the new standards and interpretations, the application of which became mandatory for the financial years beginning on January 1, 2010. Paragraph 3.1 presents all the standards being applied in the Company and having been adopted as of January 1st, 2010; however, they are not applicable in the Company's operations. Paragraph 3.2 presents the Standards, amendments to and interpretations of existing standards which are not yet effective and have not been adopted by the E.U

3.1 Changes in Accounting Principles (modifications in the published standards, effective from 2010)

Following is a description of the adopted changes in accounting principles:

- **Annual Improvements 2009**

During 2009 the IASB issued annual improvements to IFRS for 2009-a collection of adjustments to 12 Standards-being a part of the project for annual improvements to Standards. The annual improvements project by IASB aims at carrying out the necessary but non-urgent adjustments to IFRSs that will not be subject to a broader revisions project. The following standards, amendments and revisions are effective in 2010 but to not apply to the Group.

- **Adoption of the revised IFRS 3: 'Business Combinations ' and of the revised IAS 27: "Consolidated Financial Statements and Accounting for Investment in Subsidiaries'**

The revised IFRS 3 introduces a raft of changes in the accounting treatment of business combinations that will affect the amount of recognized goodwill, the results of the reference period when business acquisition is realized and future results. These changes include expensing of expenditures relative to recognition of contingent consideration fair value posterior changes in the results. The revised IAS 27 requires recognition in equity of transactions resulting in shareholding rates change in a subsidiary. Moreover, the revised standard modifies the accounting treatment of losses incurred by a subsidiary and by the subsidiary control loss. All changes of aforementioned standards will be applied in the future and will affect future acquisitions and transactions with minority shareholders. The revised Standards are expected to affect the accounting treatment of business combinations in future periods; however, such impact will be estimated when such combinations are realized.

- **IAS 39: 'Financial Instruments: Recognition and Measurement' -Amendment to IAS 39 as regards assets that meet the criteria for hedge accounting**

The amendment to IAS 39 clarifies hedge accounting issues and, in particular, inflation and one-sided risk in a hedged item. Application of this amendment is not expected to have a substantial impact on the Group's financial statements.

- ● **Amendments to IFRS 2 'Share-Based Payment'**

IASB proceeded to amend IFRS 2 regarding vesting conditions and cancellations. None of the current share-based payment programs is affected by such amendments. The Management considers that the amendments to IFRS 2 will not affect the Group’s accounting policies.

- **IFRIC 15: Agreements for the Construction of Real Estate**

IFRIC 15 aims at providing instructions regarding the following two issues:

Whether agreements for the construction of real estate fall within the scope of IAS 11 or IAS 18. When should be recognized the income arising from the agreements of real estate construction. The present Interpretation is applied upon the accounting recognition of revenues and the related expenses of enterprises undertaking the construction of real estate either directly or through subcontractors. Any agreements within IFRIC 15 scope are agreements for the construction of real estate. In addition to the construction of real estate, such agreements may include the delivery of other products or services too.

- **IFRIC 16: 'Hedges of a Net Investment in a Foreign Operation'**

Investments in foreign operations may be held either directly by a parent company or indirectly though one of its subsidiaries. The aim of IFRIC 16 is to provide guidance on the nature of hedged risks and the amount of the hedged item for which a hedging relationship may be designated, as well as on what amounts should be reclassified from equity to profit or loss as reclassification adjustments, on disposal of the foreign operation. IFRIC 16 is applied by an entity that hedges foreign exchange risk arising from a net investment in a foreign operation and wishes to qualify for hedge accounting in accordance with IAS 39. This Interpretation applies only to the hedging of net investments in foreign operations, and does not apply to other forms of hedge accounting, such as fair value or cash flow hedging.

- **IFRIC 17: 'Distribution of Non-cash Assets to Owners'**

When an enterprise announces the distribution and is bound to distribute assets to owners, it must recognize a liability for these payable dividends. The aim of IFRIC 17 is to provide guidance on when a company shall recognize dividends payable and how it should measure them, as well as how to account for the differences between the book value of the assets distributed and the book value of the dividends payable when a company pays such dividends payable.

- **IFRIC 18: 'Transfers of Assets from Customers'**

IFRIC 18 applies mainly to companies or organizations in the utility sector. The aim of this IFRIC is to clarify the requirements of IFRSs for agreements in which an entity receives from a customer an item of property, plant, and equipment that the entity must then use either to connect the customer to a network or to provide the customer with ongoing access to a supply of goods or services (such as a supply of electricity, gas or water). In some cases, the entity receives cash from a customer that must be used only to acquire or construct the item of property, plant, and equipment in order to connect the customer to a network or provide the customer with ongoing access to a supply of goods or services (or to do both). IFRIC 18 clarifies where the definition of a tangible asset is met, as well as the recognition and measurement of initial cost. It also explains how to determine the obligation for the provision of the above services in exchange for the tangible asset and how to recognize the relevant income and account for the cash received from customers.

- **Amendment to IFRS 1 'First-time Adoption of International Financial Reporting Standards' - Additional Exemptions for First-time Adopters of IFRS**

The amendment provides exemption from IFRS retrospective application in measurement of assets in oil, natural gas and leases sectors. Amendment is applied for annual periods beginning on or after January 1st, 2010. The amendment is not applied in Group operations.

3.2 Standards, modifications and interpretations of existing standards either not yet effective or not yet adopted by the E.U.

IASB issued the following new IFRS, amendments and interpretations that are not mandatory for the financial statements presented; until the issue date of these financial statements they had not been adopted by the EU.

- **IFRS 9: 'Financial Instruments'**

IASB is planning to fully substitute IAS 39 'Financial Instruments-Recognition and Measurement' by the end of 2010, due to take effect for annual financial periods starting on or after January 1st, 2013. IFRS 9 constitutes the first stage of a total project to replace IAS 39. The key stages are the following:

1st stage: Recognition and Measurement
2nd stage: Impairment methodology
3rd stage: Hedge accounting

One additional project is addressing issues pertaining to interruption of recognition.
IFRS 9 aims to reduce complexity in the accounting treatment of financial instruments providing fewer categories of financial assets and a new approach for their classification. According to the new standard, a financial entity classifies the financial assets either at amortized cost or at fair value based on:
a) the enterprise's business model for financial assets management and
b) the contractual cash flow characteristics of the financial assets (if it has not opted for defining a financial asset at fair value through P & L).
The existence of only two categories- amortized cost and fair value – means that the new standard requires a single impairment method to be used, reducing thus complexity. The impact from IFRS 9 application is being assessed by the enterprise as an impact is expected on Equity and results from the business model an entity will select for managing its financial assets. The standard is applied for annual periods beginning on or after 01/01/2013 and has not yet been approved by the E.U.

- **Amendment to IFRS 1 'First-time Adoption of International Financial Reporting Standards' - Limited Exemptions from Comparative IFRS 7 Disclosures for First-time Adopters of IFRS**

The amendment provides exemptions to first-time adopters of IFRS from the obligation to provide comparative information on disclosures required by IFRS 7 'Financial Instruments: Disclosures'. The amendment is applied for annual periods beginning on or after 01/07/2010 and has been approved by the E.U.
This amendment is not applied in the Group.

- **IAS 24 'Related Party Disclosures (revision)'**

This amendment clarifies definition of related parties and reduces disclosures in government-related entities transactions. In detail, government-related entities liability to disclose detailed information on transactions with the public sector and other government-related entities is cancelled; the related party definition is clarified and simplified and it is required not only to disclose relations, transactions and the balances between related parties but also the commitments both in the Company and consolidated financial statements. This amendment, adopted by the European Union, has an effective date of mandatory adoption as of January 1st, 2011. The revised standard application is not expected to substantially affect the financial statements.

- **IFRIC 14 (Amendment)- 'Prepayments of Minimum Funding Requirements'**

The purpose of the amendment was to lift an entity's restriction to recognize an asset deriving from voluntary prepayments to a benefits program in order to cover its minimum funding liabilities. The amendment is applied for annual periods beginning on or after 01/07/2011 and has been approved by the E.U. The interpretation is not applied in the Group.

- **IFRIC 19: Extinguishing Financial Liabilities with Equity Instruments**

Interpretation 19 addresses the accounting treatment issue in case the terms of a financial liability constitute an object of renegotiation and, as a result, the entity issues equity instruments to the creditor in order to settle, in full or in part, a financial liability. Such transactions are sometimes referred to as exchanges of 'debt claims-equity instruments' or agreements on shares exchange and their frequency increases during the financial crisis.

The amendment is applied for annual periods beginning on or after 01/07/2010 and has been approved by the E.U. The interpretation is not applied in the Group.

- **IAS 32- (Amendment) 'Financial Instruments: Presentation' - Classification of Rights Issues in Shares.**

The amendment revises the definition of financial liability in IAS 32 in order to classify some preemption rights or stock option rights (referred to as 'rights') as equity instruments. The amendment is mandatory for annual periods beginning on or after 1 February 2010. Application of the amendment will be examined as to whether it shall affect Group's consolidated financial statements. This amendment has been approved by the European Union.

- **Annual Improvements 2010**

During 2010 the IASB issued annual improvements to IFRS for 2010-a collection of adjustments to 7 Standards- being a part of the project for annual improvements to Standards. The annual improvements project by IASB aims at carrying out the necessary but non-urgent adjustments to IFRSs that will not be subject to a broader revisions project. Most of the adjustments are effective for annual periods beginning on or after January 1st, 2011 although entities are permitted to adopt them earlier. Annual improvements have not been adopted by the E.U.
The Group has no intention of applying any of the Standards or Interpretations earlier than required. According to the current Group structure and the accounting principles applied, the Management does not expect that the above Standards and Interpretations shall have significant impacts (unless stated otherwise) on the Group's Financial Statements, when they take effect.

5. Group Structure and consolidation methods used for the various companies

The Group companies included in the consolidated financial statements are as follows:

S/N	Trade name	Seat	Activity	Shareholding	Purchase Method	Participation
1	HYGEIA S.A.	Greece	Healthcare services	PARENT		PARENT
2	MITERA S.A.	Greece	Healthcare services	98.56%	Full	Direct-Indirect
3	MITERA HOLDINGS S.A	Greece	Shareholding in MITERA S.A.	100.00%	Full	Direct
4	LETO S.A	Greece	Healthcare services	87.39%	Full	Indirect
5	LETO HOLDINGS S.A	Greece	Shareholding in LETO S.A.	87.34%	Full	Indirect
6	ALPHA - LAB	Greece	Healthcare services	87.39%	Full	Indirect
7	HYGEIA HOSPITAL - TIRANA ShA.	Albania	Healthcare services	80.00%	Full	Direct
8	VALLONE Co Ltd	Cyprus	Investment services	100.00%	Full	Direct-Indirect
9	CHRYSSAFILIOTISSA INVESTMENT LTD	Cyprus	Investment services	64.57%	Full	Indirect
10	CHRYSSAFILIOTISSA PUBLIC LTD	Cyprus	Real estate and equipment	65.76%	Full	Indirect
11	LIMASSOL MEDICAL CENTRE 'ACHILLION' LTD	Cyprus	Healthcare services	65.76%	Full	Indirect
12	OBSTETRICS GYNAECOLOGY CLINIC EVANGELISMOS L	Cyprus	Investment services	100.00%	Full	Direct
13	EVANGELISMOS MANAGEMENT LTD	Cyprus	Healthcare services	60.00%	Full	Indirect
14	AKESO REAL ESTATE LTD	Cyprus	Investment services	60.00%	Full	Indirect
15	EVANGELISMOS REAL ESTATE LTD	Cyprus	Investment services	60.00%	Full	Indirect
16	STEM HEALTH S.A.	Greece	Stem cells medical technology	50.00%	Full	Direct
17	STEM HEALTH HELLAS S.A.	Greece	Stem cells medical technology	74.28%	Full	Indirect
18	STEM HEALTH UNIREA S.A.	Romania	Stem cells medical technology	25.00%	Full	Indirect
19	Y-LOGIMED (former ALAN MEDICAL S.A)	Greece	Import-Trading and Supply of medical-technological products	100.00%	Full	Direct
20	Y-PHARMA S.A.	Greece	Trading of pharmaceutical products and medical products of general use	85.00%	Full	Direct
21	ANIZ S.A.	Greece	Operation of canteens, restaurants	70.00%	Full	Direct
22	BIO-CHECK INTERNATIONAL Private Multi-Medical Facility Iatriki S.A	Greece	Healthcare services	100.00%	Full	Direct
23	Genesis Holding A.Ş.	Turkey	Investment services	50.00%	Full	Direct
24	Özel Maya Sağlık Hizmetleri ve Ticaret A.Ş.	Turkey	Healthcare services	49.995%	Full	Indirect
25	Sevgi Sağlık Hizmetleri ve Ticaret A.Ş.	Turkey	Healthcare services	49.950%	Full	Indirect
26	Ten Medikal Turizm Tekstil Sanayi ve Ticaret A.Ş.	Turkey	Healthcare services	49.995%	Full	Indirect

6. Segment Reporting

A business segment is defined as a group of assets and activities that provide goods and services which are subject to different risks and returns than other business segments. A geographical segment is defined as a geographical region in which goods and services are provided and which is subject to different risks and returns than other regions.

During 1H2010, the Group mainly operated in the healthcare services business segment, and specifically the one relating to the provision of diagnostic and therapeutic healthcare services and trade, mainly in the geographical region of Greece, as well as outside that region. The tables per business segment and geographical region follow below:

Operating Segments

Results per segment on 30.06.2010

Sales	**Healthcare segment**	**Trade segment**	**Total**
to outpatients	151,129,797	20,650,027	171,779,824
to other segments	0	17,504,567	17,504,567
Net segment sales	**151,129,797**	**38,154,594**	**189,284,391**
Depreciation and Amortization	8,741,653	457,819	**9,199,472**
Financial Income	251,938	12,733	**264,671**
Financial Expenses	4,593,973	219,309	**4,813,282**
Profit before tax for the period	(5,303,575)	1,794,250	**(3,509,325)**
Assets on 30.06.2010	823,396,708	66,806,998	**890,203,706**

Results per segment on 30.06.2009

Sales	**Healthcare segment**	**Trade segment**	**Total**
to outpatients	165,069,352	17,938,060	183,007,412
to other segments	0	15,841,611	15,841,611
Net segment sales	**165,069,352**	**33,779,671**	**198,849,023**
Depreciation and Amortization	8,153,700	279,144	**8,432,844**
Financial Income	2,971,063	36,019	**3,007,082**
Financial Expenses	8,613,641	49,460	**8,663,101**
Profit before tax for the period	22,577,335	3,659,037	**26,236,372**
Assets on 31.12.2009	787,794,432	66,526,124	**854,320,556**

The Group's sales and assets as broken down into geographical regions are as follows:

	30.06.2010		**30.06.2009**	**31.12.2009**
	Sales	**Assets**	**Sales**	**Assets**
Greece	163,208,140	771,033,552	168,504,956	750,751,018
Other countries	26,076,251	119,170,154	30,344,067	103,569,538
	189,284,391	**890,203,706**	**198,849,023**	**854,320,556**

The total amounts presented in the Group's operating segments are in accordance with the basic data presented in the financial statements as follows:

Settlement Table

Sales of segments	**30.06.2010**	**30.06.2009**
Total sales per segment	189,284,391	198,849,023
Deletion of intra-segment sales	(17,504,567)	(15,841,611)
	171,779,824	**183,007,412**

Profit before tax for the period	**30.06.2010**	**30.06.2009**
Total profit per segment	(3,509,325)	26,236,372
Deletion of intra-segment profit	(1,162,232)	(10,645,322)
	(4,671,557)	**15,591,050**

Assets	**30.06.2010**	**31.12.2009**
Total assets per segment	890,203,706	854,320,556
Deletion of intra-segment profit	(94,459,702)	(74,303,829)
	795,744,004	**780,016,727**

7. Seasonality of interim business activities

The provision of services is subject to seasonality. The Company and Group's activities are highly seasonal in the 3rd quarter of each fiscal year, when turnover is significantly lower compared to other quarters.

8. Tangible fixed assets

During the closing period, the Group and Company spent the amount of € 21.1 million and € 5.2 million respectively on the purchase of tangible fixed assets, pertaining mainly to the acquisition of medical-mechanical equipment and facility improvements.

9. Investments in subsidiaries

On 11 January 2010 it was announced that the 100% subsidiary Y – LOGIMED SA, acquired the remaining 30% of BIO – CHECK INTERNATIONAL Private Multi-medical Facility Iatriki SA share capital, against a consideration of € 450,000, assuming thus 100% control of this company.

With the application of the revised IFRS 3 'Business Combinations' no goodwill was determined for the additional acquisition rate, but Group equity has been affected and in particular the account 'Retained earnings' by € 494,208.

10. Cash balance

The actual weighted average interest rate on bank deposits stands at 1.3% for the closing period. The highest rate of Group cash balance as of 30.06.2010 is deposited in Marfin Egnatia Bank S.A.

11. Loans

In January 2009, taking into account the current market conditions in Southeast Europe, the Company proceeded with the early full repayment of the Convertible Bond Loan (hereinafter "C.B.L.") on the first annual anniversary of its issue (10.01.2009) at 102% of the Issue Price, according to the terms of the Prospectus for the C.B.L. issue.

Due to the above Convertible Loan, the company burdened the results of the period 1.1.2009 – 30.06.2009 with the corresponding interest, amounting to € 1,503,429.Therefore, the financial cost of the respective period is presented significantly increased.

12. Parent company stock options plan to BoD members and management executives

The total fair value of options granted has been calculated at € 1,429,910 and will burden the P & L of financial years 2008-2010. The charge on the period 1.1.2010-30.06.2010 amounts to € 141,784.

13. Income Tax

The Group and Company's income tax expense for the period 1.1-30.06.2009 and the respective comparative period is detailed as follows:

	THE GROUP Amounts in €		THE COMPANY Amounts in €	
	30/06/2010	30/06/2009	30/06/2010	30/06/2009
Current tax expense	1,727,699	4,778,414	1,076,032	1,164,641
Deferred tax	(798,513)	(28,884)	33,562	301,348
Income tax provision	389,608	308,697	150,000	150,000
Other taxes	3,888,098	0	1,710,433	0
Total	**5,206,892**	**5,058,227**	**2,970,027**	**1,615,989**

With the Law 3845/2010, an extraordinary contribution of social responsibility was imposed on profitable Greek businesses, calculated on the total gross income for the fiscal year 2009, if it exceeds the amount of € 100 thous., based on a tiered scale. For this windfall tax, the Group has formed a provision of € 3.8 m., recognized in the category 'Other Taxes'.

14. Liens and encumbrances

There are no pre-notations or any other encumbrances on the company's assets used as collateral against loans.

On the Group's fixed assets there are mortgages amounting to € 20.7m, against borrowing.

15. Commitments

Operating lease commitments – by the Company and Group operating as lessee.

The Group leases offices and warehouses on operating leases with several terms, readjustment provisions and renewal rights. The future minimum total rents payable according to the operating lease contracts are as follows:

	THE GROUP Amounts in €		THE COMPANY Amounts in €	
Operating lease commitments	30/06/2010	12/31/2009	30/06/2010	12/31/2009
Within one year	1,975,913	1,651,464	934,046	860,406
After one year but not more than five years	6,063,914	5,480,526	3,559,058	4,357,238
More than five years	7,385,383	6,187,439	4,299,479	4,972,994
Total operating lease commitments	**15,425,210**	**13,319,429**	**8,792,583**	**10,190,638**

	THE GROUP Amounts in €			
	30/06/2010		12/31/2009	
Finance lease commitments	**Ελάχιστες μελλοντικές καταβολές**	**Παρούσα αξία ελάχιστων μελλοντικών καταβολών**	**Ελάχιστες μελλοντικές καταβολές**	**Παρούσα αξία ελάχιστων μελλοντικών καταβολών**
Within one year	1,389,820	1,204,155	1,471,378	1,350,069
After one year but not more than five years	2,123,408	1,963,110	2,861,087	2,561,681
Total minimumlease payments	**3,513,228**	**3,167,265**	**4,332,465**	**3,911,750**
Less: Financial expenses	(345,915)	0	(420,715)	0
Total minimum lease fee payments	**3,167,313**	**3,167,265**	**3,911,750**	**3,911,750**

The Group and Company letters of guarantee on 30.06.2010 are as follows:

Guarantees	THE GROUP Amounts in € 30/06/2010	12/31/2009	THE COMPANY Amounts in € 30/06/2010	12/31/2009
Letters of guarantees on behalf of subsidiaries	24,093,201	22,394,851	23,719,546	18,000,000
Bank letters of guarantees	11,066,094	6,000,000	8,372,568	6,000,000
Guarantees for the repayment of trade liabilities	8,150,932	0	85,000	0
Guarantees given for govermant grants	99,600	99,600	0	0
Other guarantees	32,609	283,220	12,063	106,161
Total guarantees	**43,442,436**	**28,777,671**	**32,189,177**	**24,106,161**

16. Contingent liabilities

Information regarding contingent liabilities

The Group has contingent liabilities on issues arising from its usual activity. No substantial charges beyond already formed provisions are anticipated from contingent liabilities. In detail:

A) Important pending court cases as of 31.06.2010
I. Claims against HYGEIA S.A.

Cases heard by courts of second instance (final rulings issued)

(1) Imposition of Special Environmental and Traffic Application Duty by the Municipality of Maroussi

The Municipality of Maroussi imposed on our Company a Special Environmental and Traffic Application Duty amounting to € 159,354.00. The company took recourse to judicial proceedings before the Administrative Court of First Instance of Athens to appeal against the decisions by the BoD of Maroussi Municipality; the appeals were dismissed at first instance.
Appeals were lodged against the decisions made by the Athens Administrative Court of First Instance; There was a hearing by the Administrative Court of Appeals of Athens accepting by virtue of its resolutions no. 3270, 3271 and 3272/ 2005 our abovementioned appeals and hence our actions against the enrollments by the Municipality of Maroussi in the relevant lists.

II. Pending Judicial Cases of "HYGEIA S.A."

(1) Imposition of a Fine by T.S.A.Y.

The Company took recourse to judicial proceedings before the Three-member Administrative Court of First Instance of Athens against T.S.A.Y for the annulment of TSAY Board of Directors decision, regarding charging the company with an employer' contributions debt amounting to € 1,507,909.31. It should be noted that the Company has already paid this amount. Ruling No 12043/27.10.2006 by the above Court has been pronounced in relation to this recourse, dismissing it as substantially unfounded.
Subsequently, the Company lodged an appeal before the Athens Administrative Court of Appeals against ruling No 12043/2006 issued by the Athens Three-Member Administrative Court of First Instance. The appeal was heard on 9.11.2007 and the above Court issued ruling No 4634/2007 whereby partially accepting the Company's appeal, acknowledging that a sum approximately equal to € 245,000 should be refunded to the Company. We have already been communicated the court ruling and the Company appealed before the State Council claiming return of the rest of the amount we paid.

III. Claims raised by patients or successors of patients against HYGEIA S.A. (MAL PRACTICE cases)

Patients or successors of patients have judicially claimed amounts from Physicians and the Company as indemnity for direct loss and/or monetary compensation for moral damage or mental anguish, from claimed medical malpractice by doctors working with the Clinic. The amount of claims stands at circa € 170 m. and € 53.2 m. for the Group and the Company respectively. The outcome of most judicial cases is not anticipated to substantially affect the Company's financial situation, because the legal claims in question are primarily turned against physicians by patients claiming indemnity for injury and monetary compensation for moral damage or mental anguish and secondarily against the Company. Finally, it is reported that almost all associate physicians of all specialties are insured in insurance companies (mal practice) for amounts varying on a case by case basis. It is estimated that the biggest part of any amounts possibly decided by courts shall be paid by physicians' insurance companies. In any event, the company is insured against third party claims on the allegation of medical malpractice in the insurance company ETHNIKI ASFALISTIKI SA; the company reserves the right of taking recourse against physicians.

C) Non tax audited financial years

A table follows below presenting the non tax audited financial years of Hygeia Group Companies:

Company's Name	Years
D.T.C.A. HYGEIA S.A.	2009
Y-LOGIMED S.A.	2007-2009
MITERA S.A.	2008-2009
MITERA HOLDINGS S.A.	2007-2009
LETO S.A	2008-2009
LETO HOLDINGS S.A	2007-2009
A-LAB S.A.	2008-2009
BIOCHECK	2007-2009
Y-PHARMA	2007-2009
ANIZ	2007-2009
HYGEIA HOSPITAL TIRANA	2009
STEM-HEALTH SA	2008-2009
STEM-HEALTH HELLAS SA	2008-2009
STEM-HEALTH UNIREA SRL	2009

For the non tax audited financial years stated above, there is a possibility additional taxes and surcharges are imposed when such are audited and finalized. The Group annually reviews the contingent liabilities expected to arise from the audit of previous years, taking into account the respective provisions when deemed necessary. The Management considers that, apart from the provisions already created, any possible taxes likely to arise will not have a significant effect on the Group's equity, profit or loss, and cash flows.

17. Provisions

The provision for any legal disputes or disputes under arbitration as of 30.06.2010 amounts for the Group to € 10.9m; for the non tax audited financial years of Group companies as of 30.06.2010 the amount stands at € 1.4m.

18. Transactions with associates

Intra-company transactions

The following transactions and balances are the transactions of the Group's subsidiaries. Such transactions, between companies included in the Group's consolidated Financial Statements, are eliminated during the purchase method procedure.

INTRACOMPANY PURCHASES-SALES 1.1.2010 - 30.06.2010

SALE PART

BUYER	D.T.C.A HYGEIA S.A	MITERA S.A	LETO SA	LETO HOLDINGS SA	ALPHA LAB S.A	HYGEIA HOSPITAL TIRANA SA	STEM HEALTH SA	STEM HEALTH HELLAS SA	STEM HEALTH URINEA SA	Y-LOGIMED SA	Y-PHARMA S.A	ANIZ S.A	VALLONE CO LTD	EVANGELISMOS MANAGEMENT LTD	BIOCHECK SA	TOTAL
D.T.C.A HYGEIA S.A	-	85.804	16.902	-	-	3.238	-	21.000	-	3.308	-	46.500	33.465	-	-	210.217
MITERA S.A	3.181	-	421.199	299.810	-	-	-	64.500	-	-	-	-	-	-	-	788.690
LETO SA	-	-	-	854	11.865	-	-	23.700	-	5.500	-	-	-	-	-	41.919
LETO HOLDINGS S.A	-	-	481.023	-	-	-	-	-	-	-	-	-	-	-	-	481.023
ALPHA LAB S.A	122.324	19.460	93.215	-	-	-	-	-	-	-	-	-	-	-	15.634	250.633
STEM HEALTH S.A.	-	-	-	-	-	-	-	106.956	25.025	-	-	-	-	-	-	131.981
STEM HEALTH HELLAS	-	-	-	-	-	-	1.200	-	20.168	-	-	-	-	-	-	21.368
Y-LOGIMED SA	11.264.759	4.065.424	922.263	-	3.520	828.268	-	1.571	-	-	14.610	-	-	-	288	17.100.703
Y PHARMA SA	79.415	-	-	-	-	-	-	-	-	475	-	-	2.884	1.799	-	84.573
ANIZ SA	14.411	2.925	350	-	-	-	-	-	-	-	-	-	-	-	-	17.686
VALLONE CO LTD	5.209	-	-	-	-	-	-	-	-	-	-	-	-	2.853	-	8.062
AKESO REAL ESTATE LT	-	-	-	-	-	-	-	-	-	-	-	-	-	227.700	-	227.700
TOTAL	**11.489.298**	**4.173.612**	**1.934.953**	**300.664**	**15.384**	**831.506**	**1.200**	**217.727**	**45.193**	**9.283**	**-**	**46.500**	**36.349**	**232.352**	**15.922**	**19.364.555**

INTRACOMPANY ASSETS-LIABILITIES ON 30.06.2010

ASSETS

LIABILITY	D.T.C.A HYGEIA S.A	MITERA S.A	MITERA HOLDINGS	LETO	LETO HOLDINGS SA	ALPHA LAB S.A	HYGEIA HOSPITAL TIRANA SA	STEM HEALTH SA	STEM HEALTH HELLAS SA	STEM HEALTH URINEA SA	Y-LOGIMED SA	Y-PHARMA S.A	VALLONE CO LTD	EVAGELISMOS LTD	EVANGELISMOS REAL ESTATE LTD	AKESO REAL ESTATE LTD	EVAGELISMOS MANAGEMENT LTD	BIOCHECK SA	TOTAL
D.T.C.A HYGEIA S.A	-	177.344	1.120	26.517	-	197.200	21.949.082	-	60.760	-	-	-	6.887.087	-	-	-	1.192.667	-	**30.491.767**
MITERA S.A	13.311	-	-	422.623	299.810	-	-	-	239.267	-	-	-		-	-	-	-	-	**975.011**
LETO S.A	-	-	-	-	-	-	-	-	23.700	-	5.500	-	-	-	-	-	-	-	**29.200**
LETO HOLDINGS S.A	-	-	-	481.023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	**481.023**
ALPHA LAB S.A	17.344	2.890	-	13.612	-	-	-	-	-	-	-	-	-	-	-	-	-	9.427	**43.273**
STEM HEALTH S.A.	-	-	-	-	-	-	-	-	235.941	348.371	-	-	-	-	-	-	-	-	**584.312**
STEM HEALTH HELLAS S.A.	-	-	-	-	-	-	-	1.243	-	203.322	-	-	-	-	-	-	-	-	**204.565**
Y-LOGIMED SA	6.356.060	4.109.753	-	576.663	-	2.943	826.940	-	1.901	-	-	478	-	-	-	-	-	346	**11.875.084**
Y PHARMA SA	43.255	-	-	-	-	-	-	-	-	-	575	-	3.873	-	-	-	4.761	-	**52.464**
ANIZ SA	8.922	377	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	**9.299**
VALLONE CO LTD	5.209	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.550	-	**25.759**
EVANGELISMOS LTD	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	171.458	123.019	-	**294.477**
EVANGELISMOS REAL ESTATE LTD	-	-		-	-	-	-	-	-	-	-	-	-	-	-	1.700	4.618	-	**6.318**
AKESO REAL ESTATE LTD	-	-	-	-	-	-	-	-	-	-	-	-	-	33.933	-	-	683.100	-	**717.033**
EVAGELISMOS MANAGEMENT LTD	76.540	-	-	-	-	-	-		-	-	-	-	-	521.738	1.323	1.520.282	-	-	**2.119.883**
TOTAL	**6.520.641**	**4.290.364**	**1.120**	**1.520.438**	**299.810**	**200.143**	**22.776.022**	**1.243**	**561.569**	**551.693**	**6.075**	**478**	**6.890.960**	**555.671**	**1.323**	**1.693.440**	**2.028.705**	**9.773**	**47.909.467**

Transactions with associates

	GROUP 30/06/2010	COMPANY 30/06/2010
Sales of merchandises/services		
Subsidiaries	0	66,768
Other affiliated parties	283,978	28,494
Total	**283,978**	**95,261**
Other income/ income from participations		
Subsidiaries	0	143,449
Other affiliated parties	13,138	13,138
Total	**13,138**	**156,587**
Purchase of merchandises		
Subsidiaries	0	10,867,892
Total	**0**	**10,867,892**
Other expenditures		
Subsidiaries	0	621,406
Other affiliated parties	2,506,309	1,303,426
Total	**2,506,309**	**1,924,833**
Purchase of tangible & intangible assets		
Other affiliated parties	345,135	345,135
Total	**345,135**	**345,135**
Assets		
Subsidiaries	0	30,491,767
Other affiliated parties	319,456	159,947
Total	**319,456**	**30,651,714**
Liabilities		
Subsidiaries	0	6,520,641
Other affiliated parties	1,728,703	722,682
Total	**1,728,703**	**7.243.323**

Transactions with basic administration and management executives of the company and group follow below:

Compensations to administrative and management executives

The benefits offered to the Management, at Group and Company level, are analyzed as follows:

	GROUP Amounts in €		COMPANY Amounts in €	
	30/06/2010	30/06/2009	30/06/2010	30/06/2009
Salaries & wages	3,217,979	2,390,017	1,209,955	862,031
Social security cost	236,220	163,955	99,924	47,680
Retirement benefits	58,333	0	58,333	0
Stock options	141,784	286,147	141,784	286,147
Total	**3,654,316**	**2,840,119**	**1,509,996**	**1,195,858**

No loans have been granted to BoD members, or to other management executives of the Group (and their families).

19. Transactions with Marfin Popular Bank Group

	GROUP 30/06/2010	COMPANY 30/06/2010
Assets	25,569,908	18,087,240
Liabilities	127,853,655	86,615,000
Revenues	240,269	124,294
Expenses	2,401,252	1,604,525

20. Earnings / (Losses) per share

The weighted average number of total shares (ordinary shares) was used for the calculation of earnings per share. There were no impaired earnings per share in the current fiscal year.

	THE GROUP Amounts in €		THE COMPANY Amounts in €	
	30/06/2010	30/06/2009	30/06/2010	30/06/2009
Salaries & other employees benefits	3,217,979	2,390,017	1,209,955	862,031
Social security costs	236,220	163,955	99,924	47,680
Termination benefits	58,333	0	58,333	0
Stock option	141,784	286,147	141,784	286,147
Total	**3,654,316**	**2,840,119**	**1,509,996**	**1,195,858**

21. Cash flows from operating activities

Statement of Cash Flows

	Note	THE GROUP Amounts in € 30/06/2010	THE GROUP Amounts in € 30/06/2009	THE COMPANY Amounts in € 30/06/2010	THE COMPANY Amounts in € 30/06/2009
Cash flows from operating activities					
Profit (loss) before taxation from continuing operation		**4,671,557**	**15,591,050**	**4,817,902**	**14,836,839**
Profit (loss) before taxation from discontinued operation					
Adjustments for:					
Depreciation		10,367,472	9,601,013	4,136,531	3,723,290
Changes in pension obligations		535,148	639,660	348,378	312,858
Provisions		747,392	1,968,209	500,000	700,000
Unrealized Exchange gains		(558,116)	(37,372)	0	0
Unrealized Exchange losses		373,574	400,081	0	269,781
(Profit) loss on sale of property, plant and equipment		(14,524)	(22,802)	0	9,978
Share in net (profit) loss of companies accounted for by the equity method		0	(125,879)	0	0
Income from reversal of prior year's provisions		(252,141)	(88,408)	0	0
Proft / Loss from fair value valuation of financial assets at fair value through profit and loss		0	0	0	0
Profit / Loss from sale of held-for-sale financial assets		0	0	0	0
Grants amortization		(84,286)	(89,627)	(19,991)	(19,661)
Profit / Loss from sale of financial assets at fair value through profit an loss		0	0	0	0
Profit/Loss from sale part of subsidiaries		0	0	0	0
Profit / Loss from fair value valuation of derivatives		0	0	0	0
Cash flows from discontinued operations		0	0	0	0
Non-cash compensation expense		116,675	0	0	0
Deferred income taxes		0	(40,342)	0	0
Interest and similar income		(264,849)	(2,995,595)	(107,244)	(1,677,841)
Interest similar expenses		4,730,250	8,662,274	2,286,664	5,885,688
Dividends		0	0	(17,500)	(8,256,583)
Impairment of assets		0	0	0	0
Employee benefits in the form of stock options		141,784	286,147	141,784	286,147
Profit/Loss from sale of subsidiary		(119,408)	0	0	0
Profit / loss from a.f.s. portfolio at fair value		0	0	0	0
Profit / loss from investment property at fair value		0	0	0	0
Profit/Loss from fair value valuation of trading portfolio		0	0	0	0
Profit/Loss from sale of trading portfolio		0	0	0	0
Total Adjustments		**15,718,971**	**18,157,359**	**7,268,622**	**1,233,657**
Cash flows from operating activities before working capital changes		**11,047,414**	**33,748,409**	**12,086,524**	**16,070,496**
Changes in Working Capital					
(Increase) / Decrease in inventories		(209,850)	(1,069,906)	(294,740)	(63)
(Increase)/Decrease in trade receivables		(2,019,464)	(2,881,135)	(8,781,398)	(9,386,057)
(Increase)/Decrease in other receivables		184,654	(3,152,684)	0	0
Increase / (Decrease) in liabilities (excluding banks		17,788,973	6,977,699	5,387,146	4,343,898
Net Increase / (Decrease) of trading portfolio		0	0	0	0
Operating cash flows from discontinued operations		0	0	0	0
		15,744,313	***(126,026)***	***(3,688,992)***	***(5,042,222)***
Cash flows operating activities	20	**26,791,727**	**33,622,383**	**8,397,532**	**11,028,274**
Interest paid		(4,454,238)	(9,808,412)	(2,094,132)	(8,364,509)
Income tax paid		(3,661,133)	(3,523,157)	(1,170,685)	(239,560)
Net Cash flows operating activities		**18,676,356**	**20,290,814**	**5,132,715**	**2,424,205**

22. Reclassifications of accounts from the purchase cost allocation of GENESIS S.A. Group.

During the Q4' '09, a measurement was completed of the fair value of assets, recognized intangible assets and liabilities assumed by GENESIS S.A. Group during the fiscal year 2008.

According to the values resulting from the estimate, the acquisition cost was allocated to the respective accounts along with a relevant reduction in the initially recognized goodwill. Therefore, the total Income Statement for the period 01.01 - 31.06.2009 and the Statement of Financial Position of the Group for the period ended on 31.12.2009 have been adjusted accordingly.

It is highlighted that the adjustments having affected the Group P & L as of 31.06.2009 refer to a) amortizations and depreciations calculated for the recognized intangible assets and the adjusted tangible assets, burdening the results by € 183,928 and b) the calculation of deferred tax, leading to € 36,786 gain on the results.

A more detailed description of the aforementioned amounts is presented in note 11.35 on the Group's annual financial statements as of 31.12.2009.

23. Events after the Statement of Financial Position date

HYGEIA Ordinary General Meeting held on 7/6/2010 decided the Company to proceed as of August 30, 2010 to distribution of **€ 0.15 per share** in the form of constructive dividend. Moreover, the Ordinary General Meeting decided that the shareholders entitled to capital return may have the possibility to reinvest part or whole of capital return. The Board of Directors was authorized by the Ordinary General Meeting to determine the subscription price of shares, which will be 10% less than the average closing price of the Company's share in Athex of the first five (5) sessions in which the share will be traded without capital return right. It was resolved that the shares to be issued as a result of the share capital increase be admitted for trading at the Athens Stock Exchange.

On July 1st2010 the new ultramodern Hospital **HYGEIA HOSPITAL TIRANA** started operating with initial capacity of approximately 120 beds offering a General Hospital, a Pediatric and Maternity Clinic. In full swing HYGEIA HOSPITAL TIRANA will offer 220 beds, 12 operating rooms, 5 labor rooms, 16 I.C.U beds. The new hospital constitutes the largest investment (approximately € 60 m.) in the healthcare services provision sector in Albania, equipped with cutting-edge technology and is expected to become a reference standard in the entire South-East Europe, offering high quality healthcare services not only in Albania but also in the neighboring countries, such as the Former Yugoslavian Republic of Macedonia, Kosovo and Montenegro.

On July 1st 2010, MITERA HOLDINGS SA, 100% subsidiary of HYGEIA S.A, acquired 49% of 'PRIVATE MULTI-MEDICAL FACILITY OF WESTERN ATHENS PRIMARY MEDICINE S.A.' share capital against a consideration of € 699,880.

HYGEIA Group Management decided HYGEIA Hospital, MITERA and LETO Maternity Hospitals and MITERA Children's Hospital not to encumber their invoices with the new V.A.T imposed for the first time as of July 1st, 2010 in Greece on the healthcare services, offering practically an equal amount decrease in prices. In this way, HYGEIA Group hospitals combine their steady pursuit for high level healthcare services with the support required under the circumstances towards society being affected by the financial crisis.

In August 2010, 'Stem-Health S.A.', 50% subsidiary of 'HYGEIA S.A.', transferred 50% of the Romanian subsidiary Stem-Health Unirea S.A. to Centrul Medical Unirea, against a consideration of € 500,055.

On August 24th 2010, HYGEIA S.A proceeded to the signing of the coverage agreement with the bank EFG EUROBANK ERGASIAS S.A. and EUROBANK EFG CYPRUS LTD for the issuing of a Common Bond Loan amounting to ten million (€ 10.000.000) of one year duration with 3-month Euribor plus margin 3.8%.

Maroussi, August 24, 2010

THE CHAIRMAN OF THE BoD	*THE CHIEF EXECUTIVE OFFICER*	*THE CHIEF FINANCIAL OFFICER OF THE GROUP*
KONSTANTINOS STAVROU *ID No A049114*	*ARETI SOUVATZOGLOU* *ID No. N245069*	*PANTELIS DIMOPOULOS* *ID No. AB606210*
THE FINANCIAL CONTROLLER OF THE GROUP		*THE DEPUTY CHIEF FINANCIAL OFFICER OF THE GROUP*
NIKOLAOS BILALIS *ID No AA005000* *LICENSE No 58800 – CLASS A'*		*SPYRIDON KOSMAS* *ID No AZ555377* *LICENSE No 16310 – CLASS A'*

E. Data and Information of the period

DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS HYGEIA S.A.
SA Registration Number 13165/06/B/86/14
4, KIFISSIAS AVENUE & ERYTHROU STAVROU STR, GR-15123 MAROUSI, ATHENS

Data and information for the period from January 1st 2010 to June 30th 2010
(pursuant to decision 4/507/28.04.2009 by the Board of Directors of the Capital Market Commission)

The data and information below resulting from the financial statements aim at an overall presentation of the Group and parent company DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS-HYGEIA S.A financial situation and results. We, therefore, propose to readers, prior to any investment choice or transaction with the issuer, to visit the issuer's web address where the financial statements and the audit report by the chartered accountant, whenever required, are posted.

COMPANY GENERAL INFORMATION

Competent Service Prefecture:	Ministry of Development and Commerce, Public Companies and Credit
Web address:	www.hygeia.gr
Board of Directors composition:	**Chairman:** Konstantinos Stavrou **Deputy Chairman** : Vgenopoulos Andreas **BoD members:** Souvatzoglou Areti-CEO, Komninos Alexios, Efstratiadis Georgios, Michopoulos Antonios **Non executive members:** Kyprianidis Anastasios, Mavroudis Christos, Dedoulis Evangelos, Seitanidis Vassileios, Kosmidis Paraskevas **Independent non executive members:** Edipidis Alexandros, Moustakas Meletios
Approval date by the Board of Directors of the Semester Financial Statements:	August 24, 2010
Certified auditor:	Manolis Michalios (Institute of Certified Public Accountants of Greece (SOEL) registration no.2
Audit Firm:	Grant Thornton SA (Institute of Certified Public Accountants of Greece (SOEL) registration no.
Type of Audit Report:	By consent

FINANCIAL POSITION STATEMENT INFORMATION (CONSOLIDATED OR NOT CONSOLIDATED)
Amounts in €

	Group		Company	
	30/06/2010	31/12/2009	30/06/2010	31/12/2009
ASSETS				
Property, plant and equipment	266.767.867	253.497.556	105.653.103	104.147.161
Property investment	165.460	166.745	165.460	166.745
Intangible assets	147.056.958	148.298.476	2.911.535	3.264.189
Other non current assets	237.476.400	236.591.124	363.875.204	363.692.916
Inventories	11.096.140	10.758.815	2.193.476	1.898.736
Accounts Receivables	80.961.802	81.764.837	73.287.763	57.504.195
Other current assets	52.219.377	48.939.174	23.665.843	24.211.555
TOTAL ASSETS	**795.744.004**	**780.016.727**	**571.752.384**	**554.885.497**
EQUITY AND LIABILITIES				
Share capital	66.961.275	66.961.275	66.961.275	66.961.275
Other equity items	325.556.921	332.204.832	332.437.528	330.652.673
Total equity of parent company owners (a)	**392.518.196**	**399.166.107**	**399.398.803**	**397.613.948**
Minority interest (b)	27.910.828	32.200.605	0	0
Total equity (c) = (a) + (b)	**420.429.024**	**431.366.712**	**399.398.803**	**397.613.948**
Long term loans	34.893.400	35.990.429	0	0
Provisions/Other long term liabilities	76.966.969	76.007.787	18.923.120	18.580.735
Short term loans	160.306.529	156.042.191	115.300.000	108.000.000
Other short term liabilities	103.148.082	80.609.608	38.130.461	30.690.814
Total liabilities (d)	**375.314.980**	**348.650.015**	**172.353.581**	**157.271.549**
TOTAL EQUITY AND LIABILITIES (c) + (d)	**795.744.004**	**780.016.727**	**571.752.384**	**554.885.497**

CASH FLOW STATEMENT (CONSOLIDATED OR NOT CONSOLIDATED)
Amounts in €

	Group		Company	
	01/01-30/06/2010	01/01-30/06/2009	01/01-30/06/2010	01/01-30/06/2009
Operating activities				
Earnings before tax (EBT)	(4.671.557)	15.591.050	4.817.902	14.836.839
Plus / minus adjustments for:				
Depreciations	10.367.472	9.601.013	4.136.531	3.723.290
Provisions	1.282.540	2.607.869	848.378	1.012.858
Income from use of provisions of previous financial years	(252.141)	(88.408)	0	0
Results (income, expenses, profits and losses) from investment activities	(466.648)	(2.655.688)	(107.244)	(1.398.082)
Amortization of grants	(84.286)	(89.627)	(19.991)	(19.661)
Deferred tax	0	(40.342)	0	0
Dividends	0	0	(17.500)	(8.256.583)
Profit/Loss from associates	0	(125.879)	0	0
Interests on debt and similar charges	4.730.250	8.662.274	2.286.664	5.885.688
Employees' stock option plan	141.784	286.147	141.784	286.147
Plus/minus adjustments for changes in working capital accounts or changes related to operating activities:				
Decrease/ (increase) in inventories	(209.850)	(1.069.906)	(294.740)	(63)
Decrease / (increase) in receivables	(2.019.464)	(2.881.135)	(8.781.398)	(9.386.057)
(Increase / (decrease) in other current assets accounts	184.654	(3.152.684)	0	0
(Decrease) / increase in liabilities (minus banks)	17.788.973	6.977.699	5.387.146	4.343.898
Less:				
Interests on debt and similar paid up charges	(4.454.238)	(9.808.412)	(2.094.132)	(8.364.509)
Tax paid	(3.661.133)	(3.523.157)	(1.170.685)	(239.560)
Total inflow / (outflow) from operating activities (a)	18.676.356	20.290.814	5.132.715	2.424.205
Investment activities				
Acquisition of subsidiaries, associates, joint ventures and other investments	840	(22.823.993)	0	(20.964.038)
Purchase of tangible and intangible fixed assets	(21.488.291)	(21.988.545)	(5.309.917)	(5.324.372)
Investments in subsidiaries	(450.000)	(1.050.021)	0	0
Proceeds from tangible and intangible fixed assets sales	229.059	92.601	0	61.000
Dividends received	0	0	15.750	9.631.235
Grants received	100.275	164.242	0	98.304
Purchase of trading portfolio	0	(31.959)	0	0
Purchase of available for sale portfolio	0	(51.418)	0	0
Loans to associates	0	0	(10.795.522)	(1.033.742)
Interests received	83.833	1.761.342	37.549	1.677.841
Total inflow / (outflow) from investment activities (b)	(21.524.284)	(43.927.751)	(16.052.140)	(15.853.772)
Financing activities				
Share capital increase receivables	(269.478)	0	(269.478)	0
Proceeds from loans	20.946.655	247.488.635	15.200.000	220.000.000
Repayment of loans	(17.227.054)	(348.399.787)	(7.900.000)	(341.015.300)
Dividends paid to minority	(109.735)	(170.001)	0	0
Settlement of liabilities from financing leases (amortizations)	(552.291)	(431.308)	0	0
Total inflow / (outflow) from financing activities (c)	2.788.097	(101.512.461)	7.030.522	(121.015.300)
Net increase / (decrease) in cash and cash equivalents of the period (a) + (b) + (c)	(59.831)	(125.149.398)	(3.888.903)	(134.444.867)
Cash and cash equivalents at the beginning of period	29.111.297	199.576.107	21.695.860	189.807.965
Fx translation differences in cash and cash equivalents	(736)	(461.835)	0	(269.781)
Cash and cash equivalents at the end of period	29.050.730	73.964.874	17.806.957	55.093.317

INCOME STATEMENT (CONSOLIDATED OR NOT CONSOLIDATED)
Amounts in €

	Group		Company	
	01/01-30/06/2010	01/01-30/06/2009	01/01-30/06/2010	01/01-30/06/2009
Revenues	171.779.824	183.007.412	72.691.046	74.061.735
Gross profit	13.820.423	32.729.027	11.181.251	13.665.606
Profits before taxes, financing and investing results .	(427.254)	21.381.967	6.979.822	11.057.884
Profit /(Loss) before tax	(4.671.557)	15.591.050	4.817.902	14.836.839
Profit /(Loss) after tax (A)	(9.878.449)	10.532.823	1.847.875	13.220.850
- Parent company owners	(6.013.996)	10.986.730	1.847.875	13.220.850
- Minority interest	(3.864.453)	(453.907)	0	0
Other total income after tax (B)	(437.241)	(1.100.611)	0	0
Total comprehensive income after tax (A) + (B)	(10.315.690)	9.432.212	1.847.875	13.220.850
- Parent company owners	(6.090.687)	10.098.649	1.847.875	13.220.850
- Minority interest	(4.225.003)	(666.437)	0	0
Basic earnings per share after tax-basic (in €)	(0,0368)	0,0875	0,0113	0,1052
Profit before taxes, financing and investing results and depreciations (EBITDA)	9.855.932	30.893.353	11.096.362	14.761.513

	Group		Company	
	01/04-30/06/2010	01/04-30/06/2009	01/04-30/06/2010	01/04-30/06/2009
Revenues	83.078.297	93.683.535	35.529.609	37.356.802
Gross profit	3.964.330	14.486.676	5.267.024	6.639.386
Profits/(losses) before taxes, financing and investing results .	(3.420.698)	8.351.577	2.871.296	4.347.729
Profit /(Loss) before tax	(5.761.413)	5.298.918	1.581.415	10.857.163
Profit /(Loss) after tax (A)	(10.746.884)	2.481.409	(626.970)	9.422.818
- Parent company owners	(8.048.008)	3.027.746	(626.970)	9.422.818
- Minority interest	(2.698.876)	(546.337)	0	0
Other total income after tax (B)	131.410	221.817	0	0
Total comprehensive income after tax (A) + (B)	(10.615.474)	2.703.226	(626.970)	9.422.818
- Parent company owners	(6.769.156)	3.165.183	(626.970)	9.422.818
- Minority interest	(3.846.318)	(461.957)	0	0
Basic earnings per share after tax-basic (in €)	(0,0493)	0,0241	(0,0038)	0,0750
Profit before taxes, financing and investing results and depreciations (EBITDA)	1.757.080	13.112.279	4.988.401	6.271.163

STATEMENT OF CHANGES IN EQUITY (CONSOLIDATED OR NOT CONSOLIDATED)
Amounts in €

	Group		Company	
	30/06/2010	30/06/2009	30/06/2010	30/06/2009
Total equity at the beginning of the period (01.01.2010 and 01.01.2009, respectively)	431.366.712	383.338.652	397.613.948	324.316.483
Total comprehensive income after tax	(10.315.690)	9.432.212	1.847.875	13.220.850
Direct changes in Equity	0	10.549	0	0
Dividends	0	(6.281.546)	0	(6.281.546)
Share capital decrease with cash refund to shareholders	0	(15.075.709)	0	(15.075.709)
Share capital decrease	0	(36.574)	0	0
Impact from subsidiary acquisition price finalization	0	(1.974.428)	0	0
Employees' stock option plan	141.784	286.147	141.784	286.147
Share capital increase receivables	(204.805)	0	(204.805)	0
Dividends to minority shareholders of subsidiaries	(108.980)	(352.669)	0	0
Differences from purchase of shareholdings in subsidiaries	(449.997)	(10.876.028)	0	0
Convertible bond loan reserve	0	(1.161.541)	0	(1.161.541)
Total equity at the end of the period (30.06.2010 and 30.06.2009, respectively)	**420.429.024**	**357.309.065**	**399.398.803**	**315.304.684**

ADDITIONAL DATA AND INFORMATION

1. The companies that are included in the consolidation (Group Structure) for the period 01.01 – 30.06.2010 are included in Note 5 &9 of the Notes of the Interim Financial Statement Notes.
The notes also include the results of "BIO-CHECK INTERNATIONAL Private Multi-medical Facility Iatriki S.A' consolidated with the full consolidation method, in contrast to the respective comparative period of 2009, when it was included for one month.
In June 2009, the terms of Genesis Group acquisition by the Diagnostic and Therapeutic Center of Athens-Hygeia S.A Group were finalized. During the 4Q2009, was concluded the evaluation of the assets fair value, the recognized intangible assets and liabilities that were obtained from Genesis Holding A.S. Group during the fiscal year 2008. Based on the values that arose from the evaluation was conducted allocation of the acquisition cost to the respective accounts and respectively was reduced the initial recognized goodwill. As a result, the Income Statement for the period 01.01-30.06.2009 was restated. Reference in Note 22 of the Interim Condensed Financial Statements Notes.
2. HYGEIA S.A Group consolidated financial statements are included with the purchase method for the 4Q2009 in the consolidated financial statements of 'Marfin Investment Group Holdings S.A.' based in Greece, with 44.41% direct and indirect participation rate in D.T.C.A HYGEIA S.A on June 30th 2010.
3. The most important sub judice, the juridical decisions that have or may have important effect in the economic situation or in the operation of the Company and the Group amount circa to €53.2 m and €170 m respectively and they have to do with patients' or their heirs' requirements; part of the abovementioned amount is covered by Mal Practice insurance. In any event, the company is insured against third party claims on the allegation of medical malpractice in the insurance company ETHNIKI ASFALISTIKI SA; the company reserves the right of taking recourse against physicians. The Company has formed a cumulative provision of about €2.6 m for litigation. For the Group, the respective provision amount stands at circa €10.9 mn. Substantial surcharges from other litigious or under arbitration disputes and decisions of judicial instruments exceeding the provision already made are not expected to arise.
4. The Company formed a cumulative provision of €300 thous. for unaudited financial years. For the Group, the respective provision amount stands at circa €1.4 mn. A relevant analysis on the unaudited financial years of every company is presented in note 16 of the Interim Condensed Financial Statements Notes dated June 30, 2010.
5. The Group and the Company have not formed other provisions, in the meaning of paragraphs 10, 11 and 14 of IAS 37 'Provisions, Contingent Liabilities and Contingent Assets'.
6. On 30.06.2010 the Group personnel totaled 4,521 employees (30.06.2009: 4,226) and the Company's personnel totaled 1,221 employees (30.06.2009 : 1,156), respectively.
7. The revenues/expenses amounts since the beginning of financial year 2010 resulting from transactions with related parties, according to IAS 24, are analyzed in the following table:

	Group	Company
Revenues	297,116	251,849
Expenses	2,506,309	12,792,724
Receivables	319,456	30,651,714
Liabilities	1,728,703	7,243,323
Transactions and payments of senior executives and administration members	3,654,316	1,509,996

8. There are pledges on the Group's assets amounting to €20.7m. There are no pledges on the Company's assets.
9. The other total revenues for the period 01.01-30.06.2010 amount to € (437,241) and concern exchanges differences from the conversion of the subsidiaries' financial statements to Euro, being the parent company operation currency (euro). Respectively, other total revenues amount to €1,100,611 for the period 01.01-30.06.2009.
10. The Group and Parent financial statements of 30.06.2010 were approved by the Company's BoD on 24.08.2010.
11. At the end of the current period, there are no parent company shares held either by itself or by subsidiaries and affiliated entities.
12. The Company followed the basic accounting principles of the annual financial statements for the fiscal year 2009, reported in note 6.7 of the Annual Financial Statements Notes

Maroussi, August 24, 2010

BoD CHAIRMAN	CHIEF EXECUTIVE OFFICER	GROUP CFO	GROUP FINANCIAL CONTROLLER	DEPUTY CFO
KONSTANTINOS STAVROU	ARETI SOUVATZOGLOU	PANTELIS DIMOPOULOS	NIKOLAOS BILALIS	SPYRIDON KOSMAS
ID No. A 049114	ID No. N245069	ID No. AB606210	ID No. AA005000	ID No. AZ 555377
			LICENSE NUMBER 58800-CLASS A'	LICENSE NUMBER 16310-CLASS A'